学术周报 · IF≥10

神经内科领域文献阅读汇编

2026年第41周 (2026-10-09) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
37
临床研究
15
基础研究
22
IF≥20
9
IF 10-20
28
子领域
7
期刊种类
21
数据日期
2026-10-09

★本周 Top 10 高影响力文献

#论文期刊IF
1International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden D...CirculationIF 41.3
2Induced regulatory B cells stably expressing interleukin-10 reverse central nervous system autoimmun...ImmunityIF 30.6
3L-Arginine inhibits NLRP3 inflammasome activation.Nature metabolismIF 27.5
4Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Rando...JAMA neurologyIF 23.6
5Rapid Whole-Genome Sequencing in Pediatric Neurology Inpatients.JAMA neurologyIF 23.6
6Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Tri...JAMA neurologyIF 23.6
7Protecting axonal mitochondria prevents chemotherapy-driven neuropathy.Trends in cancerIF 21.6
8Alzheimer's disease target and drug discovery by leveraging multiomics and electronic health data.Nature neuroscienceIF 20.3
9Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis...Nature neuroscienceIF 20.3
10Attention-Deficit/Hyperactivity Disorder and Late-Life Cognitive Impairment.JAMA psychiatryIF 18.0

Ŧ期刊分布统计

期刊篇数IF
Science advances4IF 13.9
Ageing research reviews4IF 15.5
Stroke3IF 11.1
Advanced healthcare materials3IF 11.0
JAMA neurology3IF 23.6
Nature neuroscience2IF 20.3
Science translational medicine2IF 15.6
Acta neuropathologica2IF 10.3
Neuron2IF 16.9
Trends in cancer1IF 21.6

1脑血管病与卒中 (13篇)

临床研究 (7篇)

European journal of preventive cardiology IF 10.0 2026-10-08 PMID: 42847616
Atherosclerotic cardiovascular disease (ASCVD), encompassing coronary artery disease (CAD), cerebrovascular disease (ischemic stroke, IS; and transient ischemic attack, TIA), and peripheral artery disease (PAD) of atherosclerotic origin, remains a leading cause of morbidity and mortality worldwide despite major advances in prevention and treatment. Although atherosclerosis arises from the convergence of endothelial injury, lipid accumulation, inflammation, and thrombosis, the relative contribution of these pathogenic processes varies markedly among individuals, due to the effects of genetics, demographic, and racial factors, lifestyle behaviors and comorbidities, several of which are modifiable. The variability in the atherosclerosis underlying mechanisms results in substantial heterogeneity in clinical presentation, disease progression, and therapeutic response. Recently, ASCVD management has expanded beyond single-pathway intensification toward pathway-guided, patient-centered, multi-targeted therapeutic strategies. Over the past decade, we have witnessed the development of highly specific therapeutics, including small-molecule inhibitors, monoclonal antibodies, and RNA-based therapies, while genome-editing approaches remain at an investigational stage. Contemporary Phase 3 randomized controlled trials (RCTs) have demonstrated that several novel agents reduce cardiovascular (CV) risk, whereas others produce biological effects without improving outcomes, underscoring the need for outcome-based validation. Despite improved safety profiles and enhanced treatment adherence, the optimal integration of these therapies into clinical practice continues to evolve. In this narrative review, we evaluate evidence from established, emerging, and investigational therapeutic strategies for ASCVD prevention and treatment. We also describe the impact of endothelial-protective, lipid-lowering, anti-inflammatory, and antithrombotic, strategies on CV outcomes, with particular emphasis on differential efficacy across patient subgroups, vascular territories, and clinical settings. In addition to synthesizing evidence from contemporary clinical trials, this review proposes a novel pathway- and phenotype-based conceptual framework for individualized ASCVD management and secondary prevention. The framework integrates residual-risk phenotypes with clinical characteristics, comorbidities, vascular territory, and treatment-related considerations to support residual-risk-guided selection of complementary evidence-based therapies while balancing anticipated benefit, safety, treatment burden, and adherence.
中文摘要:动脉粥样硬化性心血管疾病(ASCVD)包括冠状动脉疾病(CAD)、脑血管病(缺血性卒中,IS;以及短暂性脑缺血发作,TIA)和动脉粥样硬化源性外周动脉疾病(PAD),尽管预防和治疗取得重大进展,它仍是全球发病和死亡的主要原因。尽管动脉粥样硬化源于内皮损伤、脂质蓄积、炎症和血栓形成的共同作用,但这些致病过程相对贡献在个体间差异显著,受遗传、人口学和种族因素、生活方式行为及合并症影响,其中若干因素可改变。动脉粥样硬化潜在机制的变异性导致临床表现、疾病进展和治疗反应存在显著异质性。近年来,ASCVD管理已超越单通路强化,转向通路导向、以患者为中心的多靶点治疗策略。过去十年,我们见证了高特异性治疗药物的发展,包括小分子抑制剂、单克隆抗体和基于RNA的疗法,而基因组编辑方法仍处于研究阶段。当代3期随机对照试验(RCT)表明,若干新型药物降低心血管(CV)风险,而其他药物产生生物学效应但未改善结局,这凸显了基于结局验证的必要性。尽管安全性和治疗依从性有所改善,这些疗法如何最佳整合进临床实践仍在不断演变。在这篇叙述性综述中,我们评估用于ASCVD预防和治疗的已确立、新兴和研究性治疗策略的证据。我们还描述内皮保护、降脂、抗炎和抗血栓策略对CV结局的影响,特别强调其在不同患者亚组、血管区域和临床场景中的疗效差异。除了综合当代临床试验的证据外,本综述提出一种新的基于通路和表型的概念框架,用于个体化ASCVD管理和二级预防。该框架整合残余风险表型与临床特征、合并症、血管区域及治疗相关考量,以支持根据残余风险选择互补的循证治疗,同时平衡预期获益、安全性、治疗负担和依从性。
Stroke IF 11.1 2026-10-08 PMID: 42845268
Stroke remains a leading cause of human disability worldwide. Additional approaches beyond acute stroke therapies are needed to improve patient outcomes. Neural repair therapies focus on promoting neural plasticity in surviving tissue rather than modifying the acute injury; examples include behavioral training, drugs, biological therapies, and neural stimulation. This review discusses principles related to patient selection, control group design, intervention timing, choice of outcome measures, experience-dependent plasticity, use of biomarkers, and statistical considerations, each of which emerges from a review of key stroke recovery trials. Patient selection strategies may benefit from incorporating neuroimaging and neurophysiology biomarkers to ensure viability of treatment targets. Modality-specific outcome measures offer advantages over global disability scales for repair-based trials. The timing of intervention is critical given evolving poststroke biology and the existence of critical periods for plasticity. Repair-based therapies benefit from pairing with concomitant experience of sufficient intensity and appropriate type to shape and reinforce brain circuits. Consideration of these key principles is expected to improve the design of trials that aim to promote neural repair and improve function after stroke. Researchers and clinicians should attend to these factors when designing and interpreting clinical trials to maximize the likelihood that neural repair therapies will improve disability after stroke.
中文摘要:脑卒中仍是全球人类残疾的主要原因。除急性卒中治疗外,还需要其他方法来改善患者结局。神经修复疗法侧重于促进存活组织中的神经可塑性,而非改变急性损伤;例子包括行为训练、药物、生物疗法和神经刺激。本综述讨论了与患者选择、对照组设计、干预时机、结局指标选择、经验依赖性可塑性、生物标志物使用和统计学考量相关的原则,这些原则均源自对关键卒中恢复试验的回顾。患者选择策略可能受益于纳入神经影像学和神经生理学生物标志物,以确保治疗靶点的可行性。对于基于修复的试验,模态特异性结局指标相比整体残疾量表具有优势。鉴于卒中后生物学的动态演变以及可塑性关键期的存在,干预时机至关重要。基于修复的疗法受益于与强度足够且类型适当的伴随经验相结合,以塑造和强化脑回路。考虑这些关键原则有望改善旨在促进神经修复和改善卒中后功能的试验设计。研究人员和临床医生在设计和解读临床试验时应关注这些因素,以最大程度提高神经修复疗法改善卒中后残疾的可能性。
Stroke IF 11.1 2026-10-08 PMID: 42845267
Stroke is a leading cause of disability worldwide. Neural repair therapies, distinct from acute stroke therapies, target surviving neural elements to promote plasticity after the acute injury has occurred. Repair therapies encompass a broad and rapidly evolving therapeutic landscape, ranging from behavioral training, drugs, and biological agents to neural stimulation. In this review, we highlight major advances across these therapeutic categories, focusing on the evidence base and readiness for clinical adoption. Intensive behavioral interventions, including constraint-induced movement therapy and telerehabilitation, result in meaningful gains even in chronic stroke. Biological therapies-growth factors, monoclonal antibodies, and stem cell approaches-show promise but face translational challenges. Pharmacological strategies targeting serotonergic and dopaminergic systems have yielded mixed results. Neural stimulation approaches span a spectrum of invasiveness, with vagus nerve stimulation now Food and Drug Administration-approved and emerging candidates including cerebellar deep brain stimulation and spinal cord epidural stimulation showing early promise. These studies have provided important lessons for neural repair trial design. Synthesizing evidence across modalities, we highlight how therapeutic advances are reshaping the landscape of poststroke recovery and identify the most promising opportunities for clinical translation. Emerging neural repair strategies stand to substantially improve function after stroke.
中文摘要:卒中是世界范围内导致残疾的主要原因。神经修复治疗不同于急性卒中治疗,其靶向存活的神经元件,以在急性损伤发生后促进可塑性。修复治疗涵盖广泛且快速演变的治疗领域,从行为训练、药物和生物制剂到神经刺激。本综述重点介绍这些治疗类别的主要进展,关注证据基础和临床应用的成熟度。强化行为干预,包括强制性诱导运动疗法和远程康复,即使在慢性卒中中也能带来有意义的功能改善。生物治疗,包括生长因子、单克隆抗体和干细胞方法,显示出前景,但面临转化挑战。靶向5-羟色胺能和多巴胺能系统的药理学策略结果不一。神经刺激方法涵盖不同的侵入性程度,其中迷走神经刺激现已获美国食品药品监督管理局批准,而新兴候选方法包括小脑深部脑刺激和脊髓硬膜外刺激,显示出早期前景。这些研究为神经修复试验设计提供了重要经验。综合不同模式的证据,我们强调治疗进展如何重塑卒中后恢复的格局,并确定最有希望的临床转化机会。新兴神经修复策略有望显著改善卒中后的功能。
Ageing research reviews IF 15.5 2026-10-07 PMID: 42843467
This review evaluates the impact of Post-Acute Sequelae of SARS-CoV-2 on adults aged 25 to 55, focusing on the potential for accelerated biological aging and an increased incidence of acute cardiovascular events. By synthesizing evidence from 110 epidemiological and mechanistic studies, we examine the interplay between viral-induced immune dysregulation, endothelial injury, and systemic physiological decline in a demographic previously considered low-risk for severe outcomes. Our analysis indicates that chronic systemic inflammation, potentially maintained by persistent viral reservoirs in immune-privileged sites, may drive aging-associated molecular changes. While accelerated telomere attrition and altered DNA methylation patterns are reported, applying validated epigenetic clocks (e.g., Horvath's, PhenoAge) yields divergent results, ranging from no disparity to slight but significant epigenetic age acceleration. Alongside these evolving metrics, elevated neurofilament light chain and GDF-15 may indicate ongoing neuronal injury and cellular stress. Concurrently, the findings highlight an elevation in cardiovascular relative risks, where sustained endothelial dysfunction and microthrombi formation appear to contribute to a higher frequency of acute events, including myocardial infarction and ischemic stroke, within these younger cohorts. The review concludes that Post-Acute Sequelae of SARS-CoV-2 may represent an emerging driver of premature biological aging and heightened vascular vulnerability. We propose an exploratory clinical framework that prioritizes targeted, symptom-driven care pathways. While early pharmacological interventions remain strictly hypothesis-generating and confined to clinical trials to prevent iatrogenic harm, utilizing advanced biomarkers to evaluate high-risk phenotypes in symptomatic patients may guide future multidisciplinary research to mitigate the long-term societal burden of post-viral decline.
中文摘要:本综述评估SARS-CoV-2急性后遗症对25至55岁成人的影响,重点关注加速生物学衰老的潜能以及急性心血管事件发生率增加。通过综合110项流行病学和机制研究证据,我们探讨病毒诱导的免疫失调、内皮损伤和全身生理衰退之间的相互作用,而该人群既往被认为严重结局低风险。我们的分析表明,慢性全身性炎症可能由免疫豁免部位持续存在的病毒储存库维持,并可能驱动衰老相关分子改变。尽管有报道称端粒加速缩短和DNA甲基化模式改变,应用经过验证的表观遗传时钟(例如Horvath时钟、PhenoAge)得到的结果并不一致,从无差异到轻微但显著的表观遗传年龄加速不等。与这些不断发展的指标同时,神经丝轻链和GDF-15升高可能提示持续存在的神经元损伤和细胞应激。同时,研究结果突出显示心血管相对风险升高,其中持续的内皮功能障碍和微血栓形成似乎促使这些较年轻队列中急性事件发生频率更高,包括心肌梗死和缺血性卒中。本综述得出结论,SARS-CoV-2急性后遗症可能是早发生物学衰老和血管易损性增高的新兴驱动因素。我们提出一个探索性临床框架,优先采用靶向、症状驱动的照护路径。虽然早期药物干预仍严格处于假设生成阶段,并仅限于临床试验以防止医源性伤害,但利用先进生物标志物评估有症状患者中的高风险表型,可能指导未来多学科研究,以减轻病毒后衰退带来的长期社会负担。
Stroke IF 11.1 2026-10-07 PMID: 42841198
Subjective social status (SSS) represents self-perceived social position and may affect poststroke recovery. Despite impacting various medical outcomes, SSS remains understudied in stroke. We hypothesized that higher SSS is associated with better stroke recovery at 3- and 12 months poststroke. In this prospective cohort study, patients were enrolled between October 2016 and February 2020. We examined associations between 3-month SSS score and clinician-reported, performance, and patient-reported outcomes at 3- and 12-month assessments. Ordinal multivariable regression analysis evaluated 3-month SSS score as a predictor of 12-month modified Rankin Scale score. The 494 participants had a median age of 63.5 years; 200 (41%) were female, and median (interquartile range) acute National Institutes of Health Stroke Scale score was 4 (2-8). Scores on SSS showed no meaningful associations with performance outcomes and some associations with clinician-reported outcomes (eg, 3-month modified Rankin Scale: ρ, -0.12 [95% CI, -0.21 to -0.03], false discovery rate-adjusted P=0.017; 12-month modified Rankin Scale: ρ12mo, -0.18 [95% CI, -0.27 to -0.09], false discovery rate-adjusted P=0.001). Conversely, higher SSS showed strong, consistent correlations with patient-reported outcomes, including less psychological distress and higher Stroke Impact Scale-Activities of Daily Living (ρ3mo, 0.18 [95% CI, 0.09-0.26]; ρ12mo, 0.17 [95% CI, 0.07-0.26]; all false discovery rate-adjusted P<0.05). Item-level analyses of Stroke Impact Scale-Activities of Daily Living revealed that SSS remained most strongly and consistently linked to complex Stroke Impact Scale-Activities of Daily Living motor tasks over time. In ordinal multivariable regression adjusted for age, sex, stroke subtype, initial severity, and the selected objective socioeconomic status proxies (eg, educational attainment, employment, and marital status), 3-month SSS score significantly predicted 12-month modified Rankin Scale score (β, 0.14 [95% CI, 0.02-0.26]; P=0.014). In patients with predominantly mild stroke, 3-month SSS score may serve as a significant social determinant of health that is associated with long-term functional recovery, a relationship closely linked with psychological distress. SSS scores at 3 months poststroke may identify vulnerable patients, enabling development, validation, and targeted application of interventions that optimize stroke recovery.
中文摘要:主观社会地位(SSS)代表自我感知的社会位置,可能影响卒中后恢复。尽管SSS影响多种医学结局,但在卒中亚人群中仍研究不足。我们假设较高的SSS与卒中后3个月和12个月更好的恢复相关。在这项前瞻性队列研究中,患者于2016年10月至2020年2月入组。我们检验了3个月SSS评分与3个月和12个月评估时临床医生报告、表现性和患者报告结局之间的关联。采用有序多变量回归分析评估3个月SSS评分作为12个月改良Rankin量表评分的预测因素。494名参与者的中位年龄为63.5岁;200名(41%)为女性,急性期美国国立卫生研究院卒中量表评分中位数(四分位距)为4(2-8)。SSS评分与表现性结局无有意义的关联,并与部分临床医生报告结局存在一定关联(例如,3个月改良Rankin量表:ρ,-0.12[95% CI,-0.21至-0.03],经错误发现率校正的P=0.017;12个月改良Rankin量表:ρ12mo,-0.18[95% CI,-0.27至-0.09],经错误发现率校正的P=0.001)。相反,较高的SSS与患者报告结局呈强且一致的关联,包括更少的心理困扰和更高的卒中影响量表-日常生活活动能力(ρ3mo,0.18[95% CI,0.09-0.26];ρ12mo,0.17[95% CI,0.07-0.26];所有经错误发现率校正的P<0.05)。对卒中影响量表-日常生活活动能力的分项分析显示,随着时间推移,SSS与复杂的卒中影响量表-日常生活活动能力运动任务保持最强且最一致的关联。在调整年龄、性别、卒中亚型、初始严重程度以及所选客观社会经济地位替代指标(例如教育程度、就业状况和婚姻状况)的有序多变量回归中,3个月SSS评分显著预测12个月改良Rankin量表评分(β,0.14[95% CI,0.02-0.26];P=0.014)。在主要为轻型卒中的患者中,3个月SSS评分可能是一个显著的健康社会决定因素,与长期功能恢复相关,这一关系与心理困扰密切相关。卒中后3个月的SSS评分可能识别脆弱患者,从而有助于开发、验证和有针对性地应用优化卒中恢复的干预措施。
Circulation IF 41.3 2026-10-06 PMID: 42639666
Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
中文摘要:植入式心脏复律除颤器(ICD)已用于肥厚型心肌病(HCM)患者以预防猝死,并已证明对许多患者可挽救生命。然而,ICD治疗的经验主要来自局限于世界特定国家或地区的相对较小的HCM队列。因此,我们试图在一个大型国际多中心HCM人群中确定ICD预防因危及生命的室性心律失常所致猝死的有效性。我们回顾性查询了25个HCM中心的数据库(美国8个、欧洲9个、亚洲4个,澳大利亚、非洲、墨西哥和南美洲各1个),以识别连续接受ICD的HCM患者(1992年至2024年),并随访7±6年(最长32年)以了解临床结局。共识别出3387例患者(63%为男性)。他们的平均左心室厚度为22±7 mm。参与者接受ICD的平均年龄为47±17岁。随访期间,550例患者(16%)经历了至少1次恰当ICD治疗(2.6%/年),包括247例因二级预防植入者中的86例(35%[6.4%/年])和3140例因一级预防植入者中的464例(15%[2.2%/年])。一级预防患者中464例发生恰当治疗,平均年龄49±17岁,首次恰当治疗的中位时间为ICD植入后4年;其中16%在植入后≥10年才接受首次恰当治疗,47%经历了多次干预。恰当ICD治疗的独立预测因素包括不明原因晕厥、左心室心尖部室壁瘤、左心室收缩功能障碍以及动态监测中的非持续性室性心动过速。在3140例一级预防患者中,2946例存活(94%),194例死亡(6%)(0.8%/年),其中68例死于HCM(0.3%/年),主要死于终末期心力衰竭(n=43)或卒中(n=9)。相比之下,11例患者(0.4%)发生猝死,在发生危及生命的室性快速性心律失常者中2.4%出现装置故障。10年和20年无HCM相关死亡的生存率分别为97%和91%。在这项迄今最大规模、纳入超过3300例连续HCM合并ICD患者的国际多中心研究中,装置治疗终止了六分之一患者的潜在致死性室性快速性心律失常,ICD患者的HCM相关死亡率较低。这些新数据证明了ICD措施的有效性,可能已有利地改变了许多全球HCM患者的自然病史。
JAMA neurology IF 23.6 2026-10-05 PMID: 42832236
Rapid whole-genome sequencing (WGS) has advanced inpatient genetic diagnosis, although most evidence comes from neonatal and pediatric intensive care unit (ICU) populations. Its utility for pediatric neurology inpatients across broader acute settings remains insufficiently established. To assess the diagnostic yield, clinical impact, and factors associated with phenotype-concordant rapid WGS diagnoses. This was a retrospective cohort study conducted from June 1, 2022, through January 17, 2026, at a tertiary medical center. Pediatric inpatients in the neonatal ICU, pediatric ICU, or general floor with an unexplained neurologic presentation were included. Those with established nongenetic etiology were excluded from analyses. Trio (77.8%), duo (9.1%), or singleton (13.1%) rapid WGS. The primary outcome was the initial phenotype-concordant diagnostic yield at the point of care. Secondary outcomes were reanalysis yield (new diagnoses from reinterpreting nondiagnostic cases prompted by a new unexplained phenotype or family request), cumulative yield, and management change. Associations were assessed by logistic regression (odds ratios [ORs] and 95% CIs). Among 175 children (median [IQR] age, 4 months [1 day-4 years]; 93 male [53.1%]) who met inclusion criteria (82 neonates, 93 nonneonates), initial rapid WGS established a phenotype-concordant diagnosis in 79 (45.1%), higher in nonneonates (49 of 93 [52.7%]) than neonates (30 of 82 [36.6%]). Preliminary results returned at mean (SD) 4.0 (1.6) days and final reports at 10.4 (4.5) days. Positive nonconcordant findings occurred in 33 children (18.9%). Reanalysis of 14 nondiagnostic cases yielded 3 additional diagnoses, for a cumulative yield of 82 of 175 children (46.9%). Most diagnoses were monogenic (63 [76.8%]). Management changed in 54 of 82 phenotype-concordant cases (65.9%; 53 at the point of care, 1 after reanalysis) and 8 of 33 (24.2%) positive nonconcordant cases. Family history was most strongly associated with diagnosis (adjusted OR [aOR], 6.46; 95% CI, 3.23-12.93; P < .001), followed by multisystem involvement (aOR, 2.85; 95% CI, 1.24-6.54; P = .01) and congenital anomaly or dysmorphism (aOR, 2.47; 95% CI, 1.07-5.68; P = .03). Hypotonia was most strongly associated in neonates (OR, 20.63; 95% CI, 5.46-77.87; P < .001); ICU admission (OR, 10.25; 95% CI, 2.79-37.67; P < .001) predominated in nonneonates. Results of this cohort study suggest that rapid WGS diagnosed nearly half of pediatric neurology inpatients and changed management in two-thirds of diagnosed cases, supporting its potential use as early diagnostic testing. Associated features may guide patient selection, and reanalysis extends yield longitudinally.
中文摘要:快速全基因组测序(WGS)已推动住院患者遗传诊断,尽管多数证据来自新生儿和儿科重症监护病房(ICU)人群。其在更广泛急性诊疗场景中儿科神经内科住院患者中的效用仍尚未充分确立。评估与表型一致的快速WGS诊断的诊断率、临床影响及相关因素。此项回顾性队列研究于2022年6月1日至2026年1月17日在某三级医疗中心开展。纳入新生儿ICU、儿科ICU或普通病房中表现为不明原因神经系统表现的儿科住院患者。已确定非遗传病因者排除在分析之外。采用三人组(77.8%)、双人组(9.1%)或单人(13.1%)快速WGS。主要结局为诊疗现场初始与表型一致的诊断率。次要结局为再分析诊断率(因新的不明原因表型或家属要求而重新解读未诊断病例所产生的新诊断)、累积诊断率及管理改变。采用logistic回归评估相关性(比值比[OR]及95%CI)。在175名符合纳入标准的儿童中(中位[IQR]年龄4个月[1天-4年];93名男性[53.1%])(82名新生儿,93名非新生儿),初始快速WGS在79名(45.1%)中建立与表型一致的诊断,非新生儿(93名中49名[52.7%])高于新生儿(82名中30名[36.6%])。初步结果平均(SD)4.0(1.6)天返回,最终报告于10.4(4.5)天返回。阳性但不一致发现见于33名儿童(18.9%)。对14例未诊断病例再分析产生3例额外诊断,累积诊断率为175名儿童中82名(46.9%)。大多数诊断为单基因病(63例[76.8%])。在82例与表型一致病例中54例(65.9%;53例在诊疗现场,1例在再分析后)管理发生改变,在33例阳性但不一致病例中8例(24.2%)管理发生改变。家族史与诊断的关联最强(校正OR[aOR],6.46;95%CI,3.23-12.93;P<.001),其次为多系统受累(aOR,2.85;95%CI,1.24-6.54;P=.01)和先天畸形或畸形面容(aOR,2.47;95%CI,1.07-5.68;P=.03)。在新生儿中肌张力低下关联最强(OR,20.63;95%CI,5.46-77.87;P<.001);在非新生儿中入住ICU占主导(OR,10.25;95%CI,2.79-37.67;P<.001)。本队列研究结果提示,快速WGS诊断了近半数儿科神经内科住院患者,并改变了三分之二已诊断病例的管理,支持其作为早期诊断检测的潜在用途。相关特征可能指导患者选择,而再分析可纵向提高诊断率。

基础研究 (6篇)

Pharmacological research IF 12.2 2026-10-07 PMID: 42843676
Ischemic stroke (IS) results from an acute interruption of cerebral blood flow and the ensuing collapse of energy metabolism. Although vascular recanalization can salvage the ischemic penumbra, its overall benefit remains constrained by a narrow therapeutic window and reperfusion injury. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, contributes to neuronal injury after IS and can amplify ischemia/reperfusion injury. By integrating energy metabolism, iron homeostasis, and redox balance, mitochondria can shape ferroptosis susceptibility within the energy-depleted, iron-dysregulated, and oxidatively stressed ischemic brain. However, most studies have examined iron metabolism and lipid peroxidation at the whole-cell level, leaving the temporal and interorganelle dimensions of mitochondrial regulation of ferroptosis insufficiently integrated. Here, we organize mitochondria-associated ferroptosis across the pathological course of IS, from metabolic reprogramming and substrate accumulation during ischemia to the reverse electron transport-associated reactive oxygen species burst during early reperfusion and subsequent disruption of mitochondrial quality control. We further examine mitochondrial crosstalk with the endoplasmic reticulum, lysosomes, lipid droplets, and nucleus, compare ferroptosis susceptibility across neurovascular unit cell populations, and map these mechanisms onto pharmacological interventions and mechanistically plausible therapeutic windows. Finally, we assess barriers to the clinical translation of mitochondria-targeted therapies and provide a stage-resolved framework for developing neuroprotective strategies in IS.
中文摘要:缺血性卒中(IS)由脑血流急性中断及随后的能量代谢崩溃所致。尽管血管再通可挽救缺血半暗带,但其总体获益仍受限于狭窄的治疗时间窗和再灌注损伤。铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式,参与IS后的神经元损伤,并可放大缺血/再灌注损伤。通过整合能量代谢、铁稳态和氧化还原平衡,线粒体可在能量耗竭、铁调节异常和氧化应激的缺血脑组织中塑造铁死亡易感性。然而,大多数研究在全细胞水平探讨铁代谢和脂质过氧化,致使线粒体调控铁死亡的时间维度和细胞器间维度尚未得到充分整合。在此,我们沿IS的病理进程梳理线粒体相关铁死亡,从缺血期间的代谢重编程和底物蓄积,到早期再灌注时与反向电子传递相关的活性氧爆发,以及随后线粒体质量控制受损。我们进一步探讨线粒体与内质网、溶酶体、脂滴和细胞核的交互对话,比较神经血管单元各细胞群对铁死亡的易感性,并将这些机制对应到药理学干预和机制上可行的治疗时间窗。最后,我们评估线粒体靶向治疗临床转化的障碍,并提供分阶段框架以制定IS的神经保护策略。
Immunity IF 30.6 2026-10-06 PMID: 42838057
The lack of approaches to produce interleukin (IL)-10-producing B cells at high frequency has hampered mechanistic investigation into the generation, fate, and activity of these regulatory cells. We screened pharmacological compounds for their ability to induce IL-10 expression in B cells. One compound, N6, promoted stable IL-10 expression in >95% of B cells. Transfer of IL-10+ B cells induced remission of experimental autoimmune encephalomyelitis. N6-induced B cells accumulated in the central nervous system (CNS) and differentiated into IL-10+ plasma cells, promoting transcriptional and phenotypic changes in myeloid cells within the CNS. The therapeutic effect of IL-10+ B cell transfer was abrogated in mice lacking IL-10 receptor expression in long-lived myeloid cells, pointing to microglia as targets of B cell-derived IL-10. Importantly, an N6 analog corrected defective IL-10 expression in B cells from multiple sclerosis patients. Our findings establish a pharmacological strategy to generate IL-10+ B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression.
中文摘要:缺乏以高频产生白细胞介素(IL)-10 的 B 细胞的方法,阻碍了对这些调节性细胞的生成、命运和活性的机制研究。我们筛选了能够诱导 B 细胞表达 IL-10 的药理学化合物。一种化合物 N6 可促使超过 95% 的 B 细胞稳定表达 IL-10。转移 IL-10+ B 细胞可诱导实验性自身免疫性脑脊髓炎缓解。N6 诱导的 B 细胞在中枢神经系统(CNS)中积聚,并分化为 IL-10+ 浆细胞,促进 CNS 内髓系细胞的转录和表型变化。在长寿命髓系细胞中缺乏 IL-10 受体表达的小鼠中,IL-10+ B 细胞转移的治疗效果被消除,提示小胶质细胞是 B 细胞来源 IL-10 的靶点。重要的是,一种 N6 类似物可纠正多发性硬化症患者 B 细胞中缺陷的 IL-10 表达。我们的发现建立了一种可生成具有治疗潜力的 IL-10+ B 细胞的药理学策略,并确定小胶质细胞是拦截神经炎症疾病进展的关键靶点。
IEEE transactions on medical imaging IF 12.4 2026-10-06 PMID: 42837229
Quantitative imaging methods, such as magnetic resonance fingerprinting (MRF), aim to extract interpretable pathology biomarkers by estimating biophysical tissue parameters from signal evolutions. However, the pattern-matching algorithms or neural networks used in such inverse problems often lack principled uncertainty quantification, which limits the trustworthiness and transparency, required for clinical acceptance. Here, we describe a physics-structured variational autoencoder (PS-VAE) designed for rapid extraction of voxelwise multi-parameter posterior distributions. Our approach integrates a differentiable spin physics simulator with self-supervised learning, and provides a full covariance that captures the inter-parameter correlations in the latent biophysical space. The method was validated in a multi-proton pool chemical exchange saturation transfer (CEST) and semisolid magnetization transfer (MT) molecular MRF study, across in-vitro phantoms, tumor-bearing mice, healthy human volunteers, and subjects with glioblastoma and Alzheimer's Disease. The resulting multi-parametric posteriors are in good agreement with those calculated using a brute-force Bayesian analysis, while providing an orders-of-magnitude acceleration in whole brain quantification. In addition, we demonstrate how monitoring the multi-parameter posterior dynamics across progressively acquired signals provides practical insights for protocol optimization and may facilitate real-time adaptive acquisition. The code and sample data are available at https://github.com/momentum-laboratory/ps-vae.
中文摘要:定量成像方法,如磁共振指纹(MRF),旨在通过从信号演化中估计生物物理组织参数来提取可解释的病理学生物标志物。然而,此类逆问题中使用的模式匹配算法或神经网络通常缺乏有原则的不确定性量化,这限制了临床接受所需的可信度和透明度。在此,我们描述了一种物理结构变分自编码器(PS-VAE),用于快速提取体素级多参数后验分布。我们的方法将可微分自旋物理模拟器与自监督学习相结合,并提供能够捕捉潜在生物物理空间中参数间相关性的完整协方差。该方法在多质子池化学交换饱和转移(CEST)和半固体磁化转移(MT)分子MRF研究中得到验证,涵盖体外模体、荷瘤小鼠、健康人类志愿者以及胶质母细胞瘤和阿尔茨海默病受试者。所得多参数后验与使用暴力贝叶斯分析计算的结果高度一致,同时在全脑定量中提供了数量级的加速。此外,我们展示了监测随逐步采集信号变化的多参数后验动态如何为协议优化提供实用见解,并可能促进实时自适应采集。代码和示例数据可在 https://github.com/momentum-laboratory/ps-vae 获取。
MedComm IF 14.1 2026-10 PMID: 42835808
Sympathetic hyperactivity following acute brain injury (ABI) impedes recovery, yet effective treatments are lacking. Recently, N6-methyladenosine (m6A) modified by fat mass and obesity-associated gene (FTO) has been demonstrated to play critical roles in multiple neurological diseases. Here, we found that sympathetic hyperactivity occurred in traumatic brain injury and intracerebral hemorrhage patients and mouse models in vivo. In mouse ABI models, the RNA demethylase FTO was upregulated in hypothalamic neurons. Through m6A methylation sequencing, we found that FTO mediated m6A demethylation of Trhr mRNA, enhancing its stability by inhibiting YTHDF2-dependent decay. This increased neuronal TRHR expression and sensitivity to TRH, culminating in sympathetic hyperactivity. Conversely, restoring hypothalamic FTO or TRHR levels alleviated this condition. We further mapped and functionally validated a monosynaptic projection from lateral hypothalamic TRHR neurons to the rostral ventrolateral medulla (RVLM), demonstrating that modulating these neurons controls sympathetic tone. Collectively, our findings elucidate a novel FTO-Trhr axis in post-ABI autonomic dysfunction and highlight a promising therapeutic target.
中文摘要:急性脑损伤(ABI)后的交感神经过度活跃会阻碍恢复,但目前缺乏有效治疗。近期,由肥胖相关基因(FTO)修饰的N6-甲基腺苷(m6A)已被证明在多种神经系统疾病中发挥关键作用。在此,我们发现创伤性脑损伤和脑出血患者及小鼠在体模型中均出现交感神经过度活跃。在小鼠ABI模型中,下丘脑神经元的RNA去甲基化酶FTO表达上调。通过m6A甲基化测序,我们发现FTO介导Trhr mRNA的m6A去甲基化,通过抑制YTHDF2依赖的降解来增强其稳定性。这增加了神经元TRHR表达及对TRH的敏感性,最终导致交感神经过度活跃。相反,恢复下丘脑FTO或TRHR水平可缓解该状况。我们进一步绘制并功能验证了从下丘脑外侧区TRHR神经元到延髓头端腹外侧区(RVLM)的单突触投射,表明调节这些神经元可控制交感张力。总之,我们的研究阐明了ABI后自主神经功能障碍中一种新的FTO-Trhr轴,并突出一个有望成药的靶点。
Advanced healthcare materials IF 11.0 2026-10-05 PMID: 42834627
Cerebral ischemia-reperfusion injury (IRI) is a key driver of poor prognosis in ischemic stroke. Idebenone (IDBN) shows promise for mitigating IRI, but its efficacy is limited by poor brain accumulation. Moreover, IDBN cannot be visually tracked, making it difficult to confirm whether it reaches the ischemic brain and exerts therapeutic effects. Here, IDBN functionalized with a reactive oxygen species (ROS)-cleavable bond is grafted onto phosphorothioate-modified DNA strands and co-assembled with ultrasmall superparamagnetic iron oxide (USPIO) to form USPIO-IDBN-SNAs, where SNAs stands for spherical nucleic acids. Exploiting upregulated class A scavenger receptors, USPIO-IDBN-SNAs target the ischemic area without targeting modifications and increase local IDBN concentration. Hydrophobic IDBN inside the SNAs limits water access to USPIO clusters, suppressing their contrast-enhancing ability. Under oxidative stress, IDBN is rapidly released and exerts remarkable protection. This release allows USPIO clusters to re-establish contact with water, activating their contrast-enhancing ability on T2-weighted imaging. Collectively, USPIO-IDBN-SNAs provide significant neuroprotection against IRI and offer a magnetic resonance imaging (MRI)-visible platform to monitor IDBN release in the ischemic brain, presenting a promising theranostic approach for precise, trackable stroke therapy.
中文摘要:脑缺血再灌注损伤(IRI)是缺血性卒中预后不良的关键驱动因素。艾地苯醌(IDBN)在减轻IRI方面显示出前景,但其疗效受限于脑内蓄积不良。此外,IDBN无法被可视化追踪,因此难以确认其是否到达缺血脑组织并发挥治疗效应。在此,将带有活性氧(ROS)可裂解键修饰的IDBN偶联到硫代磷酸修饰的DNA链上,并与超小型超顺磁性氧化铁(USPIO)共组装形成USPIO-IDBN-SNAs,其中SNAs代表球形核酸。利用上调的A类清道夫受体,USPIO-IDBN-SNAs无需靶向修饰即可靶向缺血区域,并提高局部IDBN浓度。SNAs内部疏水的IDBN限制了水接近USPIO簇,从而抑制其对比增强能力。在氧化应激下,IDBN被快速释放并发挥显著保护作用。该释放使USPIO簇重新与水接触,激活其在T2加权成像上的对比增强能力。总体而言,USPIO-IDBN-SNAs对IRI提供显著神经保护,并提供一个磁共振成像(MRI)可见平台来监测缺血脑组织中IDBN的释放,为精确、可追踪的卒中治疗提供了一种有前景的诊疗一体化策略。
Advanced healthcare materials IF 11.0 2026-10-03 PMID: 42829468
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopamine-producing neurons in the substantia nigra, causing motor symptoms. Current surgical interventions fail to restore the native nigrostriatal pathway essential for dopamine regulation. We have developed tissue-engineered nigrostriatal pathways (TE-NSPs) using hyaluronic acid hydrogel microcolumns with a collagen/laminin core encasing aggregated dopaminergic neurons and long-projecting axon tracts. TE-NSPs fabricated using human iPSC-derived dopaminergic neurons extended bundled axon tracts at a rate of 1 mm/day-twice that of neuronal aggregates on planar surfaces. Fully grown engineered microtissue exhibited nigrostriatal-like cytoarchitecture, appropriate dopaminergic phenotypes, evoked dopamine release, and innervation of striatal neurons in vitro. TE-NSPs were then evaluated in a rat 6-OHDA PD model via histology and voltammetry at 3- and 6 months post-implantation. TE-NSPs showed dopaminergic neuronal survival in the substantia nigra, preserved axon tracts within the microcolumn, and outgrowth into host striatum. Voltammetry on ex vivo brain slices containing the implanted microtissue revealed evoked dopamine release at both 3- and 6-months post-implant. This study shows engineered microtissue fabricated using human cells with an anatomically-inspired architecture and subsequently used for chronic replacement of a long-distance brain pathway in a preclinical model, potentially offering a promising future treatment for pathway reconstruction in PD.
中文摘要:帕金森病(PD)是一种进行性神经退行性疾病,特征为黑质中产生多巴胺的神经元丢失,导致运动症状。当前的手术干预无法恢复对多巴胺调节至关重要的原生黑质纹状体通路。我们利用透明质酸水凝胶微柱开发了组织工程黑质纹状体通路(TE-NSPs),其具有胶原/层粘连蛋白核心,包裹聚集的多巴胺能神经元和长投射轴突束。使用人iPSC来源的多巴胺能神经元制造的TE-NSPs以每天1毫米的速度延伸成束轴突束,是平面表面上神经元聚集体速度的两倍。完全生长的工程微组织表现出类似黑质纹状体的细胞结构、适当的多巴胺能表型、诱发的多巴胺释放,并在体外支配纹状体神经元。随后在大鼠6-OHDA PD模型中,通过组织学和伏安法在植入后3个月和6个月评估TE-NSPs。TE-NSPs显示黑质中多巴胺能神经元存活,微柱内轴突束得以保留,并向宿主纹状体长出。对包含植入微组织的离体脑切片进行伏安法显示,在植入后3个月和6个月均有诱发的多巴胺释放。本研究表明,使用人类细胞制造、具有解剖学启发结构的工程微组织,并随后在临床前模型中用于长期替代长距离脑通路,可能为PD中的通路重建提供一种有前景的未来治疗方法。

2痴呆与认知障碍 (9篇)

临床研究 (5篇)

Nature neuroscience IF 20.3 2026-10-08 PMID: 42850312
Despite prolific genomic data from individuals with Alzheimer's disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of European ancestry and 7 for African ancestry. This included epoxide hydrolase 2 (EPHX2), for which we identified a protective missense variant (p.Arg287Gln). Experiments in induced pluripotent stem cell-derived neurons and cerebral organoids from patients with AD validated the protective role of p.Arg287Gln via reduced levels of EPHX2 and phosphorylated tau (pTau-181). Pharmacological inhibition of EPHX2 improved cognitive performance in the 5xFAD mouse model of AD. Finally, by leveraging electronic health data from 111,680 patients with mild cognitive impairment, we identified 12 drugs associated with reduced AD incidence, including trazodone (targeting ADRA1A) and baclofen (targeting GABBR1). Thus, integrating multiomics data, functional validation and electronic health data identifies new approaches for treating AD.
中文摘要:尽管来自阿尔茨海默病(AD)个体的基因组数据十分丰富,但其向治疗的转化仍然滞后。在此,我们对多项AD全基因组关联研究及功能性多组学数据集应用孟德尔随机化,以提名可成药靶点,分别在欧洲血统个体中鉴定出19个靶点、在非洲血统个体中鉴定出7个靶点。其中包括环氧化物水解酶2(EPHX2),我们为其鉴定出一个保护性错义变异(p.Arg287Gln)。在来自AD患者的诱导多能干细胞衍生神经元和脑类器官中进行的实验,通过EPHX2和磷酸化tau(pTau-181)水平降低,验证了p.Arg287Gln的保护作用。对EPHX2进行药理学抑制可改善AD的5xFAD小鼠模型的认知表现。最后,通过利用111,680名轻度认知障碍患者的电子健康数据,我们鉴定出12种与AD发病率降低相关的药物,包括曲唑酮(靶向ADRA1A)和巴氯芬(靶向GABBR1)。因此,整合多组学数据、功能验证和电子健康数据,可识别治疗AD的新方法。
JAMA psychiatry IF 18.0 2026-10-07 PMID: 42842281
Attention-deficit/hyperactivity disorder (ADHD) affects tens to hundreds of millions of adults worldwide, and preliminary evidence suggests it may be associated with increased risk of mild cognitive impairment (MCI) and dementia. However, concerns regarding diagnostic ascertainment and residual confounding remain. To investigate the association of ADHD with incident cognitive impairment, defined as MCI or dementia, using electronic health record (EHR) diagnoses and genetic liability measured using genome-wide ADHD polygenic risk score (ADHD PRS) in the same individuals. This cohort study used data from the US All of Us Research Program (enrollment May 6, 2018, to October 1, 2023; EHR data from January 4, 1985, to October 1, 2023; mean [SD] follow-up 10.26 [6.75] years). A total of 187 341 participants aged 50 years and older with available EHR and genomic data were included. Data were analyzed from October 2025 to July 2026. ADHD diagnosis and ADHD PRS. Incident MCI or dementia. Among 187 341 participants (mean [SD] age, 56.41 [7.88] years; 107 266 [57%] female), 3026 (1.6%) had ADHD. Among participants with ADHD, 203 (6.7%) developed cognitive impairment, compared with 6259 (3.4%) among those without ADHD. In adjusted Cox models, ADHD was associated with a more than 4-fold higher hazard of cognitive impairment (hazard ratio [HR], 4.60; 95% CI, 3.99-5.29; P < .001). Adjustments for comorbidities, educational attainment, and health care utilization attenuated but did not eliminate the association. Similarly, ADHD PRS was associated with incident cognitive impairment (highest vs lowest quintile: HR, 1.35; 95% CI, 1.25-1.46; P < .001). Among participants who developed cognitive impairment, comorbid ADHD diagnosis was associated with a nearly 2-fold higher odds of suboptimal mental health (odds ratio [OR], 1.69; 95% CI, 1.18-2.39; P = .01), quality of life (OR, 1.66; 95% CI, 1.14-2.39; P = .02), social satisfaction (OR, 2.39; 95% CI, 1.69-3.37; P < .001), and 20% higher health care utilization (incidence rate ratio, 1.20; 95% CI, 1.09-1.34; P = .003), suggesting greater care burden beyond the elevated incidence risk. In this cohort study, convergent clinical and genetic evidence revealed ADHD was associated with a markedly increased risk of late-life cognitive impairment. Among those who develop cognitive impairment, an ADHD diagnosis was associated with worse health outcomes and greater health care utilization, supporting the need for targeted monitoring and integrated care in this population.
中文摘要:注意缺陷多动障碍(ADHD)影响全球数千万至数亿成年人,初步证据提示其可能与轻度认知障碍(MCI)和痴呆风险增加相关。然而,关于诊断确认和残余混杂的担忧仍然存在。本研究旨在利用同一批个体的电子健康记录(EHR)诊断以及通过全基因组ADHD多基因风险评分(ADHD PRS)测量的遗传易感性,探讨ADHD与新发认知障碍(定义为MCI或痴呆)的关联。这项队列研究使用了美国All of Us研究项目的数据(入组时间2018年5月6日至2023年10月1日;EHR数据时间1985年1月4日至2023年10月1日;平均[SD]随访10.26[6.75]年)。共纳入187341名年龄50岁及以上且具有可用EHR和基因组数据的参与者。数据分析时间为2025年10月至2026年7月。暴露为ADHD诊断和ADHD PRS。结局为新发MCI或痴呆。在187341名参与者中(平均[SD]年龄56.41[7.88]岁;107266[57%]为女性),3026人(1.6%)患有ADHD。在患有ADHD的参与者中,203人(6.7%)发生认知障碍,而无ADHD者中为6259人(3.4%)。在调整后的Cox模型中,ADHD与认知障碍风险增加4倍以上相关(风险比[HR],4.60;95% CI,3.99-5.29;P < .001)。对合并症、教育程度和医疗服务利用进行调整后,关联有所减弱但未消除。同样,ADHD PRS与新发认知障碍相关(最高五分位与最低五分位相比:HR,1.35;95% CI,1.25-1.46;P < .001)。在发生认知障碍的参与者中,共病ADHD诊断与心理健康不佳(比值比[OR],1.69;95% CI,1.18-2.39;P = .01)、生活质量不佳(OR,1.66;95% CI,1.14-2.39;P = .02)、社会满意度不佳(OR,2.39;95% CI,1.69-3.37;P < .001)的几率增加近2倍相关,并且医疗服务利用增加20%(发病率比,1.20;95% CI,1.09-1.34;P = .003),提示除发病风险升高外,照护负担也更重。在这项队列研究中,临床和遗传汇聚证据显示,ADHD与晚年认知障碍风险显著增加相关。在发生认知障碍的人群中,ADHD诊断与更差的健康结局和更高的医疗服务利用相关,支持对该人群进行针对性监测和整合照护的必要性。
Acta neuropathologica IF 10.3 2026-10-07 PMID: 42841982
Amyloid beta (Aβ) deposition and tau accumulation are neuropathological hallmarks of Alzheimer's disease (AD). While Aβ deposits present with a wide morphological variety, a comprehensive, cross-regional overview of Aβ plaque composition in AD and associations with clinicopathological traits are missing. In this study, we systematically documented the abundance and morphological diversity of Aβ plaques in up to 23 brain regions of 84 advanced AD cases. Deposits were segmented with a random forest pixel classifier in 4G8 diaminobenzidine stains and classified into six classes using a convolutional neural network (cored, diffuse light, diffuse dense, compact, small dense plaques, cerebral amyloid angiopathy (CAA)). Deposit counts were correlated between classes, regions, and tau load using Pearson correlation. Associations between plaque densities and co-pathologies, sex, ApoE, familial vs. sporadic cases, age at clinical onset, disease duration, and age at death were examined. Our classification model achieved a recall of 81.5% and a precision of 82.4% in the test set. Cortical brain regions showed the highest Aβ plaque loads, predominantly consisting of diffuse light and small dense plaques. Plaque densities correlated within and across the hippocampal and cortical regions. Abundances of diffuse dense, small dense, and compact plaques were positively correlated with one another, while densities of cored plaques and CAA did not correlate with other plaque classes. Only cored plaques were positively correlated with the entorhinal tau load, while other plaque classes, except CAA, showed negative correlations. Notably, female sex was associated with more diffuse plaques, and ApoE4 was associated with diffuse dense and small dense plaques. Earlier age at onset and death were associated with higher densities of diffuse light plaques. Overall, associations varied across brain regions and plaque classes. Cored plaques and CAA stand out statistically from other Aβ deposits, suggesting distinct association patterns in the course of the disease.
中文摘要:淀粉样β蛋白(Aβ)沉积和tau蛋白积聚是阿尔茨海默病(AD)的神经病理学标志。尽管Aβ沉积表现出广泛的形态多样性,但目前尚缺乏对AD中Aβ斑块组成的全面跨脑区概览及其与临床病理特征的关联。在本研究中,我们系统记录了84例晚期AD病例最多23个脑区中Aβ斑块的丰度和形态多样性。使用随机森林像素分类器在4G8二氨基联苯胺染色中对沉积物进行分割,并使用卷积神经网络将其分为六类(核心斑块、弥漫性浅淡斑块、弥漫性致密斑块、致密斑块、小致密斑块、脑淀粉样血管病(CAA))。使用Pearson相关分析对沉积计数在类别之间、脑区之间以及与tau负荷之间进行相关性分析。分析了斑块密度与共病病理、性别、ApoE、家族性与散发性病例、临床发病年龄、病程和死亡年龄之间的关联。我们的分类模型在测试集中达到81.5%的召回率和82.4%的精确率。皮层脑区显示最高的Aβ斑块负荷,主要由弥漫性浅淡斑块和小致密斑块组成。斑块密度在海马和皮层区域内及区域间存在相关性。弥漫性致密斑块、小致密斑块和致密斑块的丰度彼此呈正相关,而核心斑块和CAA的密度与其他斑块类别不相关。只有核心斑块与内嗅皮层tau负荷呈正相关,而除CAA外的其他斑块类别显示负相关。值得注意的是,女性与更多弥漫性斑块相关,ApoE4与弥漫性致密斑块和小致密斑块相关。较早的发病年龄和死亡年龄与更高的弥漫性浅淡斑块密度相关。总体而言,这些关联在不同脑区和斑块类别间存在差异。核心斑块和CAA在统计学上与其他Aβ沉积明显不同,提示其在疾病进程中具有不同的关联模式。
JAMA neurology IF 23.6 2026-10-05 PMID: 42832237
Blood-based biomarkers show high performance for detecting Alzheimer disease (AD) pathology, but evidence on their impact on diagnostic certainty, clinical management, and emotional outcomes in routine care is limited. To determine whether earlier disclosure of plasma phosphorylated tau at threonine 217 (p-tau217) and neurofilament light chain (NfL) increases etiologic diagnostic certainty, influences clinical management, and affects emotional outcomes in individuals evaluated for cognitive symptoms. This was a prospective randomized clinical trial conducted at a single memory clinic in Spain between February and October 2024, with 9 months of follow-up. Consecutive new outpatients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or mild dementia without a prior etiologic diagnosis were enrolled. Of 265 eligible participants, 220 were randomized to earlier disclosure of blood-based biomarkers at the 3-month visit or delayed disclosure at the 9-month visit. Disclosure of blood-based biomarkers for AD pathology (p-tau217) and neurodegeneration (NfL) to the treating neurologist and participant, alongside standard clinical evaluation. The primary outcome was the proportion of participants achieving a very high-confidence etiologic diagnosis (≥90%). Secondary outcomes included changes in clinical management and emotional outcomes (anxiety, depression, perceived stress, and quality of life). Among the 220 randomized participants (median [IQR] age, 73 [68-78] years; 123 [55.9%] women), baseline diagnoses were SCD (100 [45.5%]), MCI (68 [30.9%]), and mild dementia (52 [23.6%]). At 3 months, a very high-confidence etiologic diagnosis was achieved in 56 of 112 participants in the earlier-disclosure arm (50.0%) compared with 5 of 108 in the delayed-disclosure arm (4.6%) (P < .001). Diagnostic certainty converged after disclosure in both arms, except among participants with MCI, in whom higher certainty persisted in the earlier-disclosure arm. Earlier disclosure was associated with more frequent initiation of symptomatic AD treatment (16/112 [14.3%] vs 5/108 [4.6%]; difference, 9.7; 95% CI, 1.8 to 17.8; P = .01), fewer planned follow-up neuropsychological reassessments for diagnostic clarification (34/112 [30.4%] vs 57/108 [52.8%]; difference, -22.4; 95% CI, -34.4 to -9.4; P < .001), and more planned discharge from the memory clinic to primary care (35/112 [31.3%] vs 13/108 [12.0%]; difference, 19.2; 95% CI, 8.4 to 29.5; P < .001). Earlier disclosure was not associated with worse emotional outcomes. In this randomized clinical trial, earlier disclosure of blood-based biomarkers increased etiologic diagnostic certainty and led to earlier, targeted clinical management without increasing emotional distress. These findings support the integration of blood-based biomarkers into memory clinic diagnostic pathways. ClinicalTrials.gov Identifier: NCT06246019.
中文摘要:血液生物标志物在检测阿尔茨海默病(AD)病理方面表现良好,但其对常规诊疗中诊断确定性、临床管理和情绪结局影响的证据有限。旨在确定在因认知症状接受评估的个体中,较早披露血浆磷酸化tau蛋白217位点(p-tau217)和神经丝轻链(NfL)是否能提高病因学诊断确定性、影响临床管理并影响情绪结局。这是一项前瞻性随机临床试验,于2024年2月至10月在西班牙一家记忆门诊开展,随访9个月。连续纳入新发门诊患者,其患有主观认知下降(SCD)、轻度认知障碍(MCI)或轻度痴呆,且既往无病因学诊断。265名符合条件参与者中,220名被随机分配至在3个月访视时较早披露血液生物标志物,或在9个月访视时延迟披露。向治疗神经科医生和参与者披露AD病理(p-tau217)和神经退行性变(NfL)的血液生物标志物,同时进行标准临床评估。主要结局是达到极高置信度病因学诊断(≥90%)的参与者比例。次要结局包括临床管理变化和情绪结局(焦虑、抑郁、感知压力和生命质量)。在220名随机参与者中(中位[IQR]年龄73[68-78]岁;123名[55.9%]女性),基线诊断为SCD(100名[45.5%])、MCI(68名[30.9%])和轻度痴呆(52名[23.6%])。在3个月时,较早披露组112名参与者中有56名(50.0%)达到极高置信度病因学诊断,而延迟披露组108名中有5名(4.6%)(P<.001)。两组的诊断确定性在披露后趋同,但在MCI参与者中除外,其较早披露组具有持续更高的确定性。较早披露与更频繁启动AD症状性治疗相关(16/112 [14.3%] vs 5/108 [4.6%];差异,9.7;95% CI,1.8至17.8;P=.01),与更少计划进行用于明确诊断的随访神经心理重新评估相关(34/112 [30.4%] vs 57/108 [52.8%];差异,-22.4;95% CI,-34.4至-9.4;P<.001),以及与更多计划从记忆门诊转诊回初级保健相关(35/112 [31.3%] vs 13/108 [12.0%];差异,19.2;95% CI,8.4至29.5;P<.001)。较早披露与更差的情绪结局无关。在这项随机临床试验中,较早披露血液生物标志物提高了病因学诊断确定性,并带来了更早、更有针对性的临床管理,而未增加情绪困扰。这些发现支持将血液生物标志物整合到记忆门诊诊断路径中。ClinicalTrials.gov标识符:NCT06246019。
Science advances IF 13.9 2026-10-02 PMID: 42814823
Biological aging clocks offer estimations of aging and dementia, yet scalability is limited. We introduce a large-scale, cross-national speech clock derived from 2928 individuals across five Latin American countries, spanning healthy controls (HCs), mild cognitive impairment (MCI), Alzheimer's disease (AD), and non-language/language-dominant frontotemporal dementia (nldFTD/ldFTD). Multimodal acoustic and linguistic features were trained with supervised models to estimate chronological age, generating speech age gaps (SAGs) as cross-sectional markers of deviations from chronological age, with positive values interpreted as relatively older-appearing speech profiles. SAGs differentiated diagnostic groups (HCs < patient groups, with AD < nldFTD < ldFTD). This pattern was associated with clinical/cognitive domains. SAGs correlated with phosphorylated tau (p-Tau217) in AD and social exposome in HCs and AD. Brain clocks (structural/functional/combined) were associated with SAG in AD, nldFTD, and ldFTD. Epigenetic age correlated with SAGs in HCs and AD across Hannum, Retroclock, and OMICmAge, whereas ldFTD associations were limited to Retroclock and OMICmAge. These results indicate that SAGs capture cross-sectional multilevel aging-related variation and may offer a scalable, culturally adaptable, low-cost biomarker candidate for research in underrepresented global settings.
中文摘要:生物衰老时钟可提供对衰老和痴呆的估计,但其可扩展性有限。我们提出了一种大规模、跨国言语时钟,基于来自五个拉丁美洲国家的2928名个体,涵盖健康对照(HC)、轻度认知障碍(MCI)、阿尔茨海默病(AD)以及非语言/语言优势型额颞叶痴呆(nldFTD/ldFTD)。多模态声学和语言学特征通过监督模型训练来估计实际年龄,生成言语年龄差距(SAG)作为相对实际年龄偏离的横断面标志物,正值被解释为言语特征相对更显年老。SAG可区分诊断组(HC低于患者组,且AD低于nldFTD低于ldFTD)。这种模式与临床/认知领域相关。SAG在AD中与磷酸化tau(p-Tau217)相关,在HC和AD中与社会暴露组相关。脑时钟(结构/功能/联合)在AD、nldFTD和ldFTD中与SAG相关。表观遗传年龄在HC和AD中与SAG相关,涉及Hannum、Retroclock和OMICmAge,而ldFTD的关联仅限于Retroclock和OMICmAge。这些结果表明,SAG能够捕捉横断面的多层次衰老相关变异,并可能为代表性不足的全球环境中的研究提供一种可扩展、文化适应性强、低成本的候选生物标志物。

基础研究 (4篇)

Neuron IF 16.9 2026-10-07 PMID: 42097136
The ε4 allele of apolipoprotein E (APOE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD) and exacerbates AD-related pathologies. Identifying strategies to mitigate the pathogenic effects of APOE4 remains a critical challenge in the field of AD research. The rare APOE3 Christchurch (APOE3Ch) variant has been suggested to be potentially protective against AD. Our study investigated whether hepatic expression of APOE3Ch could mitigate APOE4-associated AD pathologies. We successfully delivered APOE3Ch or APOE3 into the liver by adeno-associated virus in APP/PS1 mice expressing human APOE4. We observed that hepatic APOE3Ch delivery reduced amyloid-β (Aβ) burden in the brain. Hepatic APOE3Ch expression attenuated neuroinflammation, neurodegeneration, and cognitive impairments. Mechanistically, APOE3Ch expression increased the capacity of Aβ clearance by monocytes and hepatocytes. Our findings demonstrate that hepatic APOE3Ch expression attenuates AD-type pathologies in APOE4-expressing APP/PS1 mice, highlighting liver-directed APOE3Ch gene transfer as a promising therapeutic strategy for APOE4-associated AD.
中文摘要:载脂蛋白E的ε4等位基因(APOE4)是散发性阿尔茨海默病(AD)最强的遗传风险因素,并会加剧AD相关病理。寻找减轻APOE4致病作用的策略仍是AD研究领域的关键挑战。罕见的APOE3 Christchurch(APOE3Ch)变异被认为可能对AD具有保护作用。我们的研究探讨了肝脏表达APOE3Ch是否能够减轻APOE4相关的AD病理。我们在表达人APOE4的APP/PS1小鼠中,通过腺相关病毒成功将APOE3Ch或APOE3递送至肝脏。我们观察到,肝脏递送APOE3Ch减少了脑内淀粉样β蛋白(Aβ)负荷。肝脏APOE3Ch表达减轻了神经炎症、神经退行性变和认知障碍。机制上,APOE3Ch表达提高了单核细胞和肝细胞清除Aβ的能力。我们的研究结果表明,肝脏APOE3Ch表达可减轻表达APOE4的APP/PS1小鼠中的AD型病理,突显了肝脏靶向的APOE3Ch基因转移作为APOE4相关AD的一种有前景的治疗策略。
Ageing research reviews IF 15.5 2026-10-06 PMID: 42838291
Anti-amyloid antibodies substantially reduce amyloid plaque burden, yet the resulting cognitive benefit remains modest, exposing a limitation in the conventional storage-and-deletion model of memory. We propose that Alzheimer's disease (AD) is better understood as a progressive failure of the dynamic processes that continuously reconstruct memory and bind it to conscious experience, rather than static deletion of stored content following synaptic loss. Amyloid-beta oligomers and mislocalized tau disrupt synaptic tagging, local dendritic protein synthesis, and retrieval-triggered reconsolidation well before synapses are structurally eliminated. Hippocampal sharp-wave ripples, theta-gamma coupling, and spindle-slow oscillation nesting form a shared infrastructure for memory consolidation and conscious access whose progressive failure constitutes memory failure and consciousness failure simultaneously. We trace this cascade from preclinical process dysregulation through autonoetic dissociation in mild cognitive impairment to hippocampal indexing collapse in dementia, and identify dynamic process biomarkers and therapeutic strategies, including sleep oscillation enhancement, closed-loop neurostimulation, and gamma entrainment, that the prevailing storage model cannot accommodate.
中文摘要:抗淀粉样蛋白抗体可显著减少淀粉样斑块负荷,但由此产生的认知获益仍然有限,这暴露了传统记忆「储存—删除」模型的局限。我们提出,阿尔茨海默病(AD)更适合被理解为持续重建记忆并将其与意识体验绑定的动态过程发生进行性失败,而非突触丢失后对已储存内容进行静态删除。β-淀粉样蛋白寡聚体和定位异常的tau在突触被结构性消除之前很久,就已破坏突触标记、局部树突蛋白合成以及提取触发的再巩固。海马尖波涟漪、θ-γ耦合以及纺锤波—慢振荡嵌套构成了记忆巩固与意识通达共享的基础设施,其进行性失败同时构成记忆失败和意识失败。我们追踪这一级联,从临床前阶段的过程失调,到轻度认知障碍中的自传体意识分离,再到痴呆中的海马索引崩溃,并识别出动态过程生物标志物和治疗策略,包括睡眠振荡增强、闭环神经刺激和γ夹带,而这些是当前占主导的储存模型无法容纳的。
Ageing research reviews IF 15.5 2026-10-06 PMID: 42838289
Cognitive decline in Parkinson's disease (PD), progressing from mild cognitive impairment (PD-MCI) to severe dementia (PD-D), is a debilitating core feature driven by complex neuropathological interactions. While α-synuclein accumulation is the disease's hallmark, co-pathologies involving amyloid-β and tau, alongside chronic neuroinflammation, are critical accelerators of cognitive collapse. This review positions the receptor for advanced glycation end products (RAGE) as a key molecular orchestrator bridging these disparate pathological events. Functioning as a multi-ligand sensor, RAGE binds proteotoxic aggregates (α-synuclein, amyloid-β, and tau) and damage-associated molecular patterns like HMGB1. We discuss how RAGE can drive early synaptic failure through four interconnected mechanisms: (1) triggering a "two-hit" hyperinflammatory microglial response along with TLRs; (2) initiating non-canonical intracellular neuroinflammation through RAGE-RIPK1 complex; (3) acting as a neurovascular gateway to actively transport peripheral amyloid-β and recruit circulating monocytes into the central nervous system; and (4) directly blocking long-term potentiation (LTP) and degrading dendritic spines prior to overt neuronal death. Furthermore, clinical evidence highlights the depletion of protective soluble RAGE (sRAGE) in dementia, reinforcing the prognostic value of the RAGE axis. By reframing RAGE as a convergence point for proteinopathy, neurovascular breakdown, and synaptic dysfunction, this review highlights its valuable translational potential. We conclude by exploring how selective interventions-such as RAGE-RIPK1 uncoupling peptides and sRAGE modulation-could effectively intercept the molecular cascades that precipitate dementia in prodromal PD cohorts.
中文摘要:帕金森病(PD)中的认知衰退从轻度认知障碍(PD-MCI)进展为严重痴呆(PD-D),是受复杂神经病理相互作用驱动的致残性核心特征。尽管α-突触核蛋白积聚是该病的标志,但涉及β-淀粉样蛋白和tau蛋白的共病病理以及慢性神经炎症是认知崩溃的关键加速因素。本综述将晚期糖基化终末产物受体(RAGE)定位为连接这些不同病理事件的关键分子协调者。作为多配体传感器,RAGE结合蛋白毒性聚集体(α-突触核蛋白、β-淀粉样蛋白和tau蛋白)以及损伤相关分子模式如HMGB1。我们讨论RAGE如何通过四种相互关联的机制驱动早期突触失败:(1)与TLRs共同触发「二次打击」高炎症性小胶质细胞反应;(2)通过RAGE-RIPK1复合体启动非经典细胞内神经炎症;(3)作为神经血管门户,主动转运外周β-淀粉样蛋白并将循环单核细胞募集到中枢神经系统;(4)在明显的神经元死亡之前直接阻断长时程增强(LTP)并降解树突棘。此外,临床证据强调痴呆中保护性可溶性RAGE(sRAGE)的耗竭,强化了RAGE轴的预后价值。通过将RAGE重新定义为蛋白质病变、神经血管破坏和突触功能障碍的汇聚点,本综述凸显其有价值的转化潜力。最后,我们探讨选择性干预——如RAGE-RIPK1解偶联肽和sRAGE调节——如何能够有效拦截在前驱期PD人群中促发痴呆的分子级联。
Ageing research reviews IF 15.5 2026-10-02 PMID: 42826906
Sleep and circadian disturbances are associated with cognitive decline and dementia. Narcolepsy type 1 (NT1), characterized by severe sleep-wake disruption and loss of hypocretin, would therefore be expected to predispose individuals to premature brain aging. Yet available biomarker and neuroimaging findings do not consistently support this possibility, raising questions about the role of hypocretin in mechanisms linking sleep to neurodegeneration. Beyond maintaining wakefulness, hypocretin interacts with inflammatory circuits, metabolic regulation, synaptic plasticity, amyloid processing, and circadian organization. Moreover, wake continuity and neuronal activity during this state may be relevant to the production and release of proteins implicated in neurodegeneration. The coexistence of profound sleep-wake abnormalities and an inconsistent neurodegenerative biomarker profile makes NT1 a unique human condition for investigating these relationships. Understanding this apparent paradox may provide new perspectives on how hypocretin, sleep-wake dynamics, neuronal signaling, and circadian biology relate to long-term brain health and dementia.
中文摘要:睡眠和昼夜节律紊乱与认知下降和痴呆相关。1型发作性睡病(NT1)以严重的睡眠-觉醒紊乱和下丘脑分泌素缺失为特征,因此预期会使个体易于过早出现脑老化。然而,现有的生物标志物和神经影像学发现并不一致地支持这一可能性,从而对下丘脑分泌素在连接睡眠与神经退行性变的机制中的作用提出了疑问。除了维持觉醒外,下丘脑分泌素还与炎症环路、代谢调节、突触可塑性、淀粉样蛋白加工和昼夜节律组织相互作用。此外,觉醒连续性和该状态下的神经元活动可能与神经退行性变相关蛋白的产生和释放有关。严重的睡眠-觉醒异常与不一致的神经退行性变生物标志物谱共存,使NT1成为研究这些关系的一种独特人类状况。理解这一明显悖论可能为下丘脑分泌素、睡眠-觉醒动态、神经元信号传导和昼夜节律生物学如何与长期脑健康和痴呆相关提供新视角。

3帕金森病与运动障碍 (5篇)

临床研究 (1篇)

Science advances IF 13.9 2026-10-02 PMID: 42814818
Misfolded alpha-Synuclein (α-Syn) accumulation is the defining molecular pathology of Parkinson's disease (PD), yet blood-based assays remain challenged by the high background of peripheral α-Syn originating mainly from red blood cells. Neuronal extracellular vesicles (EVs) circulating in blood offer a biologically enriched source of brain-derived α-Syn proteoforms, but their ultralow abundance has hindered reliable detection. Here, we introduce an organic electrochemical transistor-based multiparametric diagnostic assay that simultaneously detects total, aggregated, and serine-129-phosphorylated α-Syn proteoforms in serum L1CAM+ EVs. The platform achieves low femtomolar sensitivity in buffer and robust analytical performance in clinical specimens. In a cohort of 66 individuals, including prodromal and clinically diagnosed patients with PD, combining the three proteoform readouts distinguished PD from controls with 90.9% accuracy (88.6% sensitivity and 90.9% specificity). By electronically amplifying and resolving multiple neuronal α-Syn signatures in blood, this assay enables a minimally invasive diagnostic tool for early-stage PD and provides a path toward therapeutic intervention during the window when disease-modifying treatments are likely to be most effective.
中文摘要:错误折叠的α-突触核蛋白(α-Syn)积聚是帕金森病(PD)的定义性分子病理,但基于血液的检测仍受到主要来源于红细胞的外周α-Syn高背景的挑战。血液中循环的神经元细胞外囊泡(EVs)提供了富含脑源性α-Syn蛋白变体的生物学来源,但其超低丰度阻碍了可靠检测。在此,我们介绍一种基于有机电化学晶体管的多参数诊断检测法,可同时检测血清L1CAM+ EVs中的总α-Syn、聚集型α-Syn和丝氨酸129磷酸化α-Syn蛋白变体。该平台在缓冲液中达到低飞摩尔级灵敏度,并在临床标本中具有稳健的分析性能。在一个包含66名个体的队列中,包括前驱期和临床诊断的PD患者,结合三种蛋白变体读数可将PD与对照区分,准确率为90.9%(灵敏度88.6%,特异性90.9%)。通过在血液中电子放大并解析多种神经元α-Syn特征,该检测法为早期PD提供了一种微创诊断工具,并为在疾病修饰治疗可能最有效的窗口期进行治疗干预提供了路径。

基础研究 (4篇)

Science translational medicine IF 15.6 2026-10-07 PMID: 42842725
Microglia are the primary immune cells of the brain, but their role in Parkinson's disease is not fully understood. Chronic microglial activation is toxic to neurons, but in the early stages of pathology, microglia also exert beneficial functions. We used induced pluripotent stem cell (iPSC)-derived coculture models to investigate how human microglia respond to α-synuclein aggregates that form de novo inside human dopaminergic neurons with α-synuclein gene triplication or are triggered by fibrils. We found that microglia cleared Ser129-phosphorylated α-synuclein aggregates through a contact-dependent mechanism. This process was fine-tuned by sensing (P2RY12) and inhibitory (CD22) signals and involved selective phagocytosis of neuronal subcompartments (trogocytosis), independently of TREM2 or phosphatidylserine. In the presence of intraneuronal α-synuclein aggregates, microglia exhibited morphological and transcriptional changes indicative of activation. Using single-cell sequencing, we identified a cluster of disease-associated microglia (DAM) responsible for this beneficial phenotype and the Parkinson's disease GWAS candidate glycoprotein nonmetastatic melanoma protein B (GPNMB) as a key effector of aggregate clearance by microglial lysosomes. GPNMB interacted with Ser129-phosphorylated α-synuclein in iPSC-derived microglia exposed to aggregate-laden dopaminergic neurons and was up-regulated in substantia nigra microglia of individuals with incidental Lewy bodies or Parkinson's disease. Microglia-specific GPNMB knockdown using CRISPRi reduced intraneuronal aggregate clearance. GPNMB-mediated trogocytosis was negatively regulated by an autocrine IL-10 signaling loop, whereas IL-10 receptor blockade enhanced the phagocytic response. Together, our study identifies a subtype of human microglia capable of removing intraneuronal aggregates and potential therapeutic targets.
中文摘要:小胶质细胞是脑内主要的免疫细胞,但其在帕金森病中的作用尚未完全清楚。慢性小胶质细胞激活对神经元具有毒性,但在病理早期阶段,小胶质细胞也发挥有益功能。我们使用诱导多能干细胞(iPSC)来源的共培养模型,研究人类小胶质细胞如何对α-突触核蛋白聚集体作出反应;这些聚集体可在具有α-突触核蛋白基因三拷贝的人类多巴胺能神经元内从头形成,或由纤维触发。我们发现,小胶质细胞通过接触依赖机制清除Ser129磷酸化的α-突触核蛋白聚集体。该过程受到感受信号(P2RY12)和抑制信号(CD22)的精细调节,并涉及对神经元亚区室的选择性吞噬(胞啃作用),且不依赖TREM2或磷脂酰丝氨酸。在神经元内存在α-突触核蛋白聚集体时,小胶质细胞表现出提示激活的形态学和转录变化。利用单细胞测序,我们鉴定出一群负责这种有益表型的疾病相关小胶质细胞(DAM),并将帕金森病GWAS候选分子糖蛋白非转移性黑色素瘤蛋白B(GPNMB)确定为小胶质细胞溶酶体清除聚集体的关键效应分子。在暴露于富含聚集体的多巴胺能神经元的iPSC来源小胶质细胞中,GPNMB与Ser129磷酸化的α-突触核蛋白相互作用;在偶发路易小体或帕金森病个体的黑质小胶质细胞中,GPNMB表达上调。使用CRISPRi在小胶质细胞中特异性敲低GPNMB可减少神经元内聚集体的清除。GPNMB介导的胞啃作用受到自分泌IL-10信号环路的负向调节,而阻断IL-10受体则增强了吞噬反应。总之,我们的研究鉴定出一种能够清除神经元内聚集体的人类小胶质细胞亚型以及潜在治疗靶点。
Nature metabolism IF 27.5 2026-10-06 PMID: 42839106
Nutritional status and metabolic homeostasis are intricately associated with the inflammatory response. However, the direct mechanistic link between nutrition, metabolism and inflammation remains unclear. Here, we show that the amino acid L-arginine (L-Arg) is a potent endogenous inhibitor of the NLRP3 inflammasome, a central component of the inflammatory signalling pathway. We show that L-Arg binds directly to the Asp31 site of the NLRP3 protein, blocking its interaction with the adaptor ASC and subsequent inflammasome assembly and activation. L-Arg supplementation inhibits the NLRP3 inflammasome activation in macrophages, while deprivation promotes it. Treatment with L-Arg in mice alleviates monosodium urate crystal-induced arthritis and aluminium-induced peritonitis. In addition, L-Arg supplementation alleviates neuroinflammation and motor deficits in mouse models of Parkinson's disease, whereas L-Arg deprivation exacerbates pathology. In patients with Parkinson's disease, L-Arg levels are reduced in serum. Our study establishes L-Arg supplementation as a promising therapeutic avenue for managing NLRP3-driven inflammatory pathologies.
中文摘要:营养状态和代谢稳态与炎症反应密切相关。然而,营养、代谢与炎症之间的直接机制联系仍不清楚。在此,我们证明氨基酸L-精氨酸(L-Arg)是NLRP3炎症小体的强效内源性抑制剂,而NLRP3炎症小体是炎症信号通路的中心组分。我们表明L-Arg直接结合NLRP3蛋白的Asp31位点,阻断其与接头蛋白ASC的相互作用以及随后的炎症小体组装和激活。补充L-Arg可抑制巨噬细胞中NLRP3炎症小体激活,而缺乏L-Arg则促进其激活。在小鼠中给予L-Arg治疗可减轻尿酸盐晶体诱导的关节炎和铝诱导的腹膜炎。此外,补充L-Arg可减轻帕金森病小鼠模型中的神经炎症和运动缺陷,而L-Arg缺乏则加重病理。在帕金森病患者中,血清L-Arg水平降低。我们的研究确定补充L-Arg是管理NLRP3驱动炎症病理的一条有前景的治疗途径。
Acta neuropathologica IF 10.3 2026-10-06 PMID: 42837018
Superoxide dismutase 1 (SOD1), originally regarded as an antioxidant enzyme, is now recognized as a multifunctional protein whose conformational instability and aggregation contribute to neurodegeneration. The emerging evidence suggests that SOD1 pathology extends beyond amyotrophic lateral sclerosis, supporting a role in multiple neurodegenerative diseases. This review summarizes current neuropathological evidence of SOD1 co-pathologies in the human brain, with particular emphasis on its associations with TAR DNA-binding protein 43 (TDP-43), tau, alpha-synuclein, amyloid-β, and other aggregation-prone proteins. We examine the distribution of pathological SOD1 species across neurodegenerative diseases, their coexistence in affected brain regions, and potential mechanisms underlying these interactions, including oxidative stress, impaired proteostasis, aberrant phase separation, and cross-seeding. We also discuss emerging observations of SOD1 pathology in neurological conditions beyond classical neurodegenerative diseases, raising the possibility that SOD1 misfolding represents a broader cellular response to neuronal injury. Collectively, the available evidence supports a shift from viewing SOD1 as a disease-specific protein to considering it a potential participant in interconnected proteopathic networks. Although the functional significance of SOD1 co-pathologies remains incompletely understood, elucidating the molecular basis of aggregation may provide new insights into disease onset and progression, improving our understanding of neurodegenerative mechanisms, and facilitating the development of biomarkers and the identification of therapeutic targets across diverse proteinopathies.
中文摘要:超氧化物歧化酶1(SOD1)最初被视为一种抗氧化酶,如今已被认识到是一种多功能蛋白,其构象不稳定性和聚集可促进神经退行性变。新出现的证据提示,SOD1病理并不局限于肌萎缩侧索硬化,还支持其在多种神经退行性疾病中发挥作用。本综述总结了当前关于人脑中SOD1共病理的神经病理学证据,尤其强调其与TAR DNA结合蛋白43(TDP-43)、tau、α-突触核蛋白、淀粉样β蛋白及其他易聚集蛋白的关联。我们考察了病理性SOD1种类在不同神经退行性疾病中的分布、其在受累脑区中的共存情况,以及这些相互作用潜在的机制,包括氧化应激、蛋白稳态受损、异常相分离和交叉播种。我们还讨论了在经典神经退行性疾病之外的其他神经系统疾病中观察到的SOD1病理的新发现,这提示SOD1错误折叠可能代表对神经元损伤的更广泛细胞反应。总体而言,现有证据支持将SOD1从一种疾病特异性蛋白转变为相互关联的蛋白病变网络中的潜在参与者。尽管SOD1共病理的功能意义仍未被完全理解,但阐明其聚集的分子基础可能为疾病发生和进展提供新见解,增进我们对神经退行性机制的理解,并促进生物标志物开发以及跨多种蛋白病变的治疗靶点识别。
Redox biology IF 16.2 2026-10-03 PMID: 42843275
Protein tyrosine nitration is a post-translational modification associated with conditions of oxidative and inflammatory stress, driven by the production of reactive oxygen and nitrogen species (ROS and RNS). Once considered primarily a footprint of oxidative damage, tyrosine nitration is increasingly recognized as a selective modification that, in specific biological contexts, can alter protein structure, stability, enzymatic activity, and interaction networks. Mechanistically, nitration occurs through peroxynitrite-dependent and heme-peroxidase-dependent pathways and preferentially targets specific tyrosine residues based on local protein structure, solvent accessibility, and microenvironmental chemistry. Accumulating evidence has identified disease-specific nitration signatures across multiple pathological contexts. In neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, nitration of proteins such as tau, α-synuclein, manganese superoxide dismutase, ATP synthase, glyceraldehyde-3-phosphate dehydrogenase, heat shock proteins, and cytoskeletal components contributes to mitochondrial dysfunction, protein aggregation, metabolic failure, and neuronal loss. Similarly, in cardiovascular and pulmonary diseases, protein tyrosine nitration disrupts vascular and epithelial homeostasis by impairing endothelial signaling, fibrinolysis, lipid metabolism, and barrier integrity through modification of key regulatory proteins. By influencing phosphorylation-dependent signaling, enzymatic function, and protein-protein interactions, tyrosine nitration contributes to the connection between redox imbalance and progressive cellular and tissue dysfunction. This review summarizes current mechanistic insights into site-specific protein tyrosine nitration, highlights the emerging disease-associated nitroproteome, and discusses how advances in analytical and structural approaches are redefining nitration as a functional regulatory modification. Understanding the molecular determinants and consequences of tyrosine nitration may enable the development of targeted diagnostics and therapeutic strategies across diverse human diseases.
中文摘要:蛋白质酪氨酸硝化是一种翻译后修饰,与氧化和炎症应激状态相关,由活性氧和活性氮(ROS和RNS)的产生驱动。它曾主要被视为氧化损伤的痕迹,但如今越来越多地被认为是一种选择性修饰,在特定生物学背景下可改变蛋白质结构、稳定性、酶活性和相互作用网络。在机制上,硝化通过过氧亚硝酸盐依赖性和血红素过氧化物酶依赖性途径发生,并基于局部蛋白质结构、溶剂可及性和微环境化学优先靶向特定酪氨酸残基。不断积累的证据已在多种病理背景中鉴定出疾病特异性硝化特征。在神经退行性疾病中,包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化,tau、α-突触核蛋白、锰超氧化物歧化酶、ATP合酶、甘油醛-3-磷酸脱氢酶、热休克蛋白和细胞骨架组分等蛋白质的硝化,促进线粒体功能障碍、蛋白质聚集、代谢失败和神经元丢失。类似地,在心血管和肺部疾病中,蛋白质酪氨酸硝化通过修饰关键调节蛋白,损害内皮信号传导、纤维蛋白溶解、脂质代谢和屏障完整性,从而破坏血管和上皮稳态。通过影响磷酸化依赖性信号传导、酶功能和蛋白质-蛋白质相互作用,酪氨酸硝化促成了氧化还原失衡与进行性细胞和组织功能障碍之间的联系。本综述总结了当前关于位点特异性蛋白质酪氨酸硝化的机制见解,强调了新出现的疾病相关硝基蛋白质组,并讨论了分析和结构方法的进展如何重新定义硝化,将其视为一种功能性调节修饰。理解酪氨酸硝化的分子决定因素和后果,可能有助于开发针对多种人类疾病的靶向诊断和治疗策略。

4神经肌肉病与周围神经 (4篇)

临床研究 (1篇)

EBioMedicine IF 11.2 2026-10-08 PMID: 42849176
The gut microbiota modulates peripheral immunity, which is altered in amyotrophic lateral sclerosis (ALS). Faecal microbiota transplantation (FMT) may exert immunological effects, but its impact in ALS remains unclear. FETR-ALS was a multicentre, randomised, masked, sham-controlled proof-of-concept trial conducted at four Italian ALS centres. Adults with ALS of 18 months duration or less and forced vital capacity of at least 70% predicted were randomly assigned (2:1) to receive FMT or a sham procedure (SP). The intervention consisted of two nasojejunal administrations of screened-donor faecal suspension at baseline and month 6, without antibiotic preconditioning. The primary endpoint was change in circulating Tregs among CD4+ T cells at 6 months. Secondary endpoints included safety, ALS Functional Rating Scale-Revised slope, respiratory and nutritional measures, survival, and exploratory biomarker profiles. Analyses followed the intention-to-treat principle. gov identifier: NCT03766321. Between 2020 and 2024, 43 individuals were screened and 42 were enrolled and randomly assigned to FMT (n = 28; mean age 56.1 years [SD 8.2]; 14 [50%] male) or SP (n = 14; 59.6 years [9.1]; eight [57%] male). Overall, 29 participants completed the second procedure and 6-month follow-up, and Treg measurements were available for 28. The primary outcome was not met: at 6 months, 8/18 (44%) participant receiving FMT versus 2/10 (20%) receiving SP achieved a ≥20% increase in circulating Tregs (odds ratio [OR] 3.20, 95% CI 0.59-25.36; p = 0.21). Mean Treg increase was 2.36 percentage points higher with FMT (95% CI 0.19-4.55; p = 0.04). ALSFRS-R declined by -1.07 points/month in the SP group and -0.76 points/month in the FMT group, with a between-group difference in monthly decline of 0.31 points/month favouring FMT (95% CI 0.11-0.51; p = 0.002). Conversely, at month 6, the MRC score was lower in the FMT group than in the SP group (0.75 versus 0.89; mean difference -0.13, 95% CI -0.26 to 0.00; p = 0.042). FMT was associated with 32 adverse events (12.5% severe) versus 14 (28.6% severe) in SP, mostly gastrointestinal or infectious. In this exploratory trial, FMT was not associated with major safety concerns. Although the primary endpoint was not met, FMT was associated with a modest increase in circulating Tregs. Italian Ministry of Health.
中文摘要:肠道微生物群调节外周免疫,而外周免疫在肌萎缩侧索硬化(ALS)中发生改变。粪菌移植(FMT)可能发挥免疫学效应,但其在ALS中的影响仍不清楚。FETR-ALS是一项在意大利4个ALS中心开展的多中心、随机、盲法、假操作对照的概念验证试验。病程不超过18个月且用力肺活量至少为预测值70%的成人ALS患者按2:1随机分配接受FMT或假操作(SP)。干预包括在基线和第6个月两次经鼻空肠给予筛选供者粪菌悬液,未进行抗生素预处理。主要终点为6个月时CD4+ T细胞中循环Treg的变化。次要终点包括安全性、ALS功能评分量表修订版(ALSFRS-R)斜率、呼吸和营养指标、生存以及探索性生物标志物谱。分析遵循意向性治疗原则。gov标识符:NCT03766321。2020年至2024年间,43人接受筛选,42人入组并随机分配至FMT组(n=28;平均年龄56.1岁[标准差8.2];14例[50%]男性)或SP组(n=14;59.6岁[9.1];8例[57%]男性)。总体上,29名参与者完成了第二次操作和6个月随访,28名可获得Treg测量数据。主要结局未达到:6个月时,接受FMT的8/18例(44%)与接受SP的2/10例(20%)参与者达到循环Treg增加≥20%(优势比[OR] 3.20,95%CI 0.59-25.36;p=0.21)。FMT组平均Treg增幅高2.36个百分点(95%CI 0.19-4.55;p=0.04)。SP组ALSFRS-R每月下降-1.07分,FMT组每月下降-0.76分,两组每月下降差异为0.31分/月,有利于FMT(95%CI 0.11-0.51;p=0.002)。相反,第6个月时,FMT组MRC评分低于SP组(0.75对0.89;平均差异-0.13,95%CI -0.26至0.00;p=0.042)。FMT与32起不良事件相关(12.5%为严重),SP组为14起(28.6%为严重),大多为胃肠道或感染性事件。在这项探索性试验中,FMT未与重大安全性问题相关。尽管未达到主要终点,FMT与循环Treg适度增加相关。意大利卫生部。

基础研究 (3篇)

Science advances IF 13.9 2026-10-09 PMID: 42842648
Herpes simplex virus 1 (HSV-1) infections of the central nervous system cause encephalitis and are associated with increased risk of neurodegeneration, yet the molecular consequences of lytic infection in human neurons remain incompletely defined. We map the transcriptomic, proteomic, and surface-proteome changes induced by HSV-1 across the lytic infection cycle in human induced pluripotent stem cell-derived cortical glutamatergic neurons. HSV-1 drives extensive plasma-membrane remodeling, including the removal of voltage-gated sodium, potassium, and calcium channels, resulting in a profound loss of synchronous calcium signaling. We identify the viral ubiquitin-ligase adaptor pUL56 as the principal effector of this process: pUL56-dependent degradation of ion channels abolishes coordinated calcium signaling, whereas mutation of its E3-ligase-binding motifs preserves synchrony. Furthermore, expression of pUL56 alone is sufficient to abolish neuronal electrical activity. These findings establish pUL56 as a potent viral suppressor of neuronal excitability.
中文摘要:1型单纯疱疹病毒(HSV-1)感染中枢神经系统可引起脑炎,并与神经退行性变风险增加相关,但裂解性感染在人神经元中的分子后果仍未完全明确。我们在人诱导多能干细胞来源的皮层谷氨酸能神经元中,绘制了HSV-1在整个裂解感染周期诱导的转录组、蛋白质组和表面蛋白质组变化。HSV-1驱动广泛的质膜重塑,包括移除电压门控钠、钾和钙通道,导致同步化钙信号显著丧失。我们确定病毒泛素连接酶衔接蛋白pUL56是该过程的主要效应因子:pUL56依赖性的离子通道降解消除了协调的钙信号,而其E3连接酶结合基序突变则保留了同步性。此外,单独表达pUL56就足以消除神经元电活动。这些发现确立了pUL56是一种强效的神经元兴奋性病毒抑制因子。
Trends in cancer IF 21.6 2026-10-08 PMID: 42850090
Peripheral neuropathy is a poorly understood yet extraordinarily relevant obstacle to the effective implementation of cytotoxic chemotherapy in patients with cancer. Recent findings from Heles et al. demonstrate that safe neuroactive molecules that promote mitochondrial fitness in axons effectively prevent peripheral neuropathy in preclinical tumor models, thereby supporting clinical translation.
中文摘要:周围神经病变是一种人们知之甚少、却与癌症患者有效实施细胞毒性化疗极其相关的障碍。Heles等人的最新研究结果表明,促进轴突线粒体健康的、安全的神经活性分子可在临床前肿瘤模型中有效预防周围神经病变,从而支持临床转化。
Nature neuroscience IF 20.3 2026-10-07 PMID: 42844425
Disrupted axonal transport and astrocyte dysfunction are implicated in amyotrophic lateral sclerosis (ALS). Here we show these processes are linked-human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs). Conversely, isogenic gene-corrected astrocytes or boosting astrocytic mitochondrial bioenergetics rescue axonal mitochondrial transport deficits in C9ORF72 MNs. Our results delineate a non-cell-autonomous role for astrocytes in regulating mitochondrial transport along axons in ALS models.
中文摘要:轴突运输受损和星形胶质细胞功能障碍与肌萎缩侧索硬化(ALS)有关。在此,我们表明这些过程相互关联——携带C9ORF72突变的人诱导多能干细胞来源星形胶质细胞会破坏共培养运动神经元(MNs)中的线粒体轴突运输和线粒体功能。相反,同基因基因校正的星形胶质细胞或增强星形胶质细胞线粒体生物能量学可挽救C9ORF72 MNs中的轴突线粒体运输缺陷。我们的结果阐明了星形胶质细胞在ALS模型中调节沿轴突的线粒体运输方面具有非细胞自主作用。

5多发性硬化与神经免疫 (2篇)

临床研究 (1篇)

JAMA neurology IF 23.6 2026-10-05 PMID: 42832215
Preventing irreversible disability accumulation is a primary treatment goal in multiple sclerosis (MS). To assess 10-year safety and efficacy of ocrelizumab (OCR) in patients with relapsing MS (RMS). In 2 phase 3 multicenter randomized clinical trials (OPERA I and II), patients were randomized to OCR or interferon beta-1a (IFN) throughout a 2-year double-blind period (DBP) and entered an open-label extension (OLE) to receive OCR for up to an additional 8 years. Study periods were August 2011 to December 2022, with clinical cutoff on July 15, 2023. Data analyses were run between March 2023 and May 2026. Patients with RMS, aged 18 to 55 years, with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, and at least 1 relapse within the year before screening were eligible for inclusion. OCR (600 mg every 24 weeks) or IFN (44 µg 3 times weekly) in the DBP, then OCR during the OLE. Outcomes included time to onset of 48-week confirmed disability progression (CDP) or progression independent of relapse activity (PIRA); time to reach EDSS score of 4.0 and 6.0; relapse rates; and incidence of adverse events (AEs) and serious AEs. A total of 1656 patients were randomized, and 1651 patients received either OCR (n = 825) or IFN (n = 826). A total of 1325 patients (80.0%) entered the OLE, of whom 853 (64.4%) completed the studies. A total of 1093 of 1656 patients (66.0%) were female; mean (SD) baseline age was 37.1 (9.2) years vs 37.2 (9.2) years in the OCR vs IFN arms, respectively. Over 10 years, continuous OCR (OCR-OCR) significantly reduced the hazard of 48-week CDP by 24% compared with delayed initiation (IFN-OCR; hazard ratio, 0.76; 95% CI, 0.61-0.95; P = .02), with 680 patients (82.2%) receiving OCR-OCR remaining free of 48-week CDP and 712 (86.1%) free of PIRA. OCR-OCR treatment reduced the hazard of progressing to key disability milestones, including EDSS of 4.0 (34%; hazard ratio, 0.66; 95% CI, 0.43-1.03; P = .06) and 6.0 (43%; hazard ratio, 0.57; 95% CI, 0.40-0.82; P = .002), with 502 (93.3%) and 774 (94.2%) retaining scores less than 4.0 and 6.0, respectively. In patients receiving OCR-OCR, relapse rates decreased from 0.139 at year 1 to 0.016 at year 10. Rates of AEs and SAEs, including serious infections, did not increase over the 8-year OLE. In the OPERA I and II randomized clinical trials, continuous OCR treatment over 10 years provided greater benefit in preserving function than a 2-year delay in initiating OCR, reinforcing the importance of early high-efficacy treatment. ClinicalTrials.gov Identifiers: NCT01247324 and NCT01412333.
中文摘要:预防不可逆的残疾累积是多发性硬化(MS)的主要治疗目标。评估奥瑞利珠单抗(OCR)在复发型MS(RMS)患者中的10年安全性和疗效。在2项3期多中心随机临床试验(OPERA I和II)中,患者被随机分配接受OCR或干扰素β-1a(IFN)治疗,完成为期2年的双盲期(DBP)后进入开放标签扩展期(OLE),接受OCR治疗最多额外8年。研究期间为2011年8月至2022年12月,临床数据截止日期为2023年7月15日。数据分析于2023年3月至2026年5月进行。入组标准为:RMS患者,年龄18至55岁,扩展残疾状态量表(EDSS)评分为0至5.5,且筛查前1年内至少发生1次复发。DBP期间接受OCR(每24周600 mg)或IFN(44 µg,每周3次),随后在OLE期间接受OCR。结局指标包括48周确认的残疾进展(CDP)或独立于复发活动的进展(PIRA)的发生时间;达到EDSS评分4.0和6.0的时间;复发率;以及不良事件(AE)和严重不良事件的发生率。共1656例患者被随机分组,1651例患者接受了OCR(n=825)或IFN(n=826)治疗。共1325例患者(80.0%)进入OLE,其中853例(64.4%)完成了研究。1656例患者中1093例(66.0%)为女性;OCR组与IFN组的平均(SD)基线年龄分别为37.1(9.2)岁与37.2(9.2)岁。在10年期间,与延迟启动治疗(IFN-OCR)相比,持续OCR治疗(OCR-OCR)使48周CDP风险显著降低24%(风险比0.76;95% CI 0.61-0.95;P=.02),其中680例(82.2%)接受OCR-OCR治疗的患者保持无48周CDP,712例(86.1%)保持无PIRA。OCR-OCR治疗降低了进展至关键残疾里程碑的风险,包括EDSS 4.0(降低34%;风险比0.66;95% CI 0.43-1.03;P=.06)和6.0(降低43%;风险比0.57;95% CI 0.40-0.82;P=.002),分别有502例(93.3%)和774例(94.2%)保持评分低于4.0和6.0。在接受OCR-OCR治疗的患者中,复发率从第1年的0.139降至第10年的0.016。在8年OLE期间,AE和严重AE(包括严重感染)的发生率未增加。在OPERA I和II随机临床试验中,与延迟2年启动OCR相比,持续OCR治疗10年在保护功能方面提供了更大获益,进一步强调了早期高效治疗的重要性。ClinicalTrials.gov注册号:NCT01247324和NCT01412333。

基础研究 (1篇)

Science advances IF 13.9 2026-10-09 PMID: 42842659
Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.
中文摘要:诱导抗原特异性免疫耐受是在多发性硬化症(MS)等疾病中逆转自身反应性免疫反应的最精确方法。将红细胞(RBC)与MS免疫显性肽混合物偶联,是在患者中诱导抗原特异性免疫耐受的一种有前景的方法。在此,我们表明,当预防性给药时,与致病抗原偶联的红细胞能有效阻止实验性自身免疫性脑脊髓炎的发生,而在治疗性给药时可改善疾病症状。肽偶联红细胞(pcRBC)的致耐受活性具有抗原特异性,并依赖于细胞剂量和肽剂量。库普弗细胞(KC)是pcRBC的主要吞噬细胞,其摄取pcRBC不需要补体成分3、SIRPα以及Stabilin 1和2。KC对于耐受的诱导不可或缺,该过程伴随程序性死亡配体1上调以及致耐受转录转变。我们的发现确立了KC是pcRBC诱导免疫耐受的核心介质,并为该治疗策略在自身免疫性疾病中的应用提供了机制见解。

6神经遗传/影像与基础转化 (2篇)

基础研究 (2篇)

Science translational medicine IF 15.6 2026-10-07 PMID: 42842720
Tolerogenic dendritic cell (tolDC) vaccines are a promising antigen-specific therapy for multiple sclerosis (MS), yet their efficacy is limited by poor homing to secondary lymphoid organs and rapid loss of the tolerogenic phenotype in native inflamed lymph nodes. Here, we developed a 3D-printed tolerogenic artificial lymph node (tol-aLN) that creates a protected immune niche for durable tolerance induction. tolDCs were loaded onto a porous gelatin methacrylate scaffold engineered for sustained C-C motif chemokine ligand 21 (CCL21) release, recruiting naïve CD4+ T cells and shielding tolDCs from an inflammatory lymph node. Geometric optimization of an orthogonal lattice scaffold enhanced spatially confined DC-T cell interactions, promoting robust and stable induction of regulatory T cells (Treg cells). In experimental autoimmune encephalomyelitis (EAE), tol-aLN implantation attenuated disease even at advanced stages by inducing antigen-specific Foxp3+ Treg cells that trafficked to the spleen, lymph nodes, and central nervous system (CNS). Conditional Treg cell depletion abolished therapeutic efficacy, indicating that Treg cells are necessary mediators of tol-aLN-induced protection. Long-term studies revealed sustained remission without impairing systemic immunity. In a myelin oligodendrocyte glycoprotein (amino acids 1 to 125) (MOG1-125)-induced EAE model, multivalent tol-aLN also efficiently suppressed inflammatory B cells and autoantibody production, reprogramming CNS B cells toward a regulatory state. Single-cell transcriptomics further revealed a global reduction in interferon-stimulated gene activity and restoration of homeostatic microglial phenotypes. Collectively, tol-aLN offers a scalable, antigen-specific platform for immune tolerance and CNS protection, with translational potential for MS and other autoimmune diseases.
中文摘要:耐受性树突状细胞(tolDC)疫苗是一种有前景的多发性硬化(MS)抗原特异性疗法,但其疗效受到向次级淋巴器官归巢不良以及在天然炎症性淋巴结中耐受性表型快速丢失的限制。在此,我们开发了一种3D打印的耐受性人工淋巴结(tol-aLN),可创建一个受保护的免疫微环境以持久诱导免疫耐受。我们将tolDC加载到一种多孔明胶甲基丙烯酰(GelMA)支架上,该支架经工程化改造可持续释放C-C基序趋化因子配体21(CCL21),从而招募初始CD4+ T细胞并保护tolDC免受炎症性淋巴结的影响。正交晶格支架的几何优化增强了空间受限的DC-T细胞相互作用,促进调节性T细胞(Treg细胞)稳健且稳定的诱导。在实验性自身免疫性脑脊髓炎(EAE)中,即使在晚期阶段,植入tol-aLN也可通过诱导抗原特异性Foxp3+ Treg细胞减轻疾病,这些细胞迁移至脾脏、淋巴结和中枢神经系统(CNS)。条件性清除Treg细胞可消除治疗效果,表明Treg细胞是tol-aLN诱导保护所必需的介导者。长期研究显示可持续缓解且不损害全身免疫。在髓鞘少突胶质细胞糖蛋白(氨基酸1至125)(MOG1-125)诱导的EAE模型中,多价tol-aLN还能有效抑制炎症性B细胞和自身抗体产生,并将CNS B细胞重编程为调节性状态。单细胞转录组学进一步揭示干扰素刺激基因活性整体降低,并恢复稳态小胶质细胞表型。总体而言,tol-aLN提供了一种可扩展、抗原特异性的免疫耐受和CNS保护平台,具有用于MS和其他自身免疫性疾病的转化潜力。
Neuron IF 16.9 2026-10-07 PMID: 42259289
Neurons and glia work together to dynamically regulate neural circuit assembly and maintenance. In this study, we show that Drosophila exhibit large-scale synapse formation and elimination as part of normal CNS circuit maturation and that glia use conserved molecules to regulate these processes. Using a high-throughput ELISA-based in vivo screening assay, we identify new glial genes that regulate synapse numbers in Drosophila in vivo, including the scavenger receptor ortholog Croquemort (Crq). Crq acts as an essential regulator of glial-dependent synapse elimination during development, with glial Crq loss leading to excess CNS synapses and progressive seizure susceptibility in adults. Loss of Crq in glia also prevents age-related synaptic, but not neuronal, loss in the adult brain. This work provides new insights into the cellular and molecular mechanisms that underlie synapse development and maintenance across the lifespan and identifies glial Crq as a key regulator of these processes.
中文摘要:神经元与胶质细胞协同工作,动态调控神经环路的组装与维持。在本研究中,我们表明果蝇在正常中枢神经系统环路成熟过程中会出现大规模突触形成与消除,并且胶质细胞利用保守分子来调控这些过程。我们采用基于ELISA的高通量体内筛选试验,鉴定出新的调控果蝇体内突触数量的胶质基因,其中包括清道夫受体直系同源物Croquemort(Crq)。Crq是发育过程中胶质细胞依赖性突触消除的必要调控因子,胶质细胞中Crq缺失会导致中枢神经系统突触过多,并使成年果蝇逐渐出现癫痫易感性。胶质细胞中Crq缺失还可阻止成年大脑中与年龄相关的突触丢失,但不影响神经元丢失。这项工作为理解贯穿生命周期的突触发育与维持所依赖的细胞与分子机制提供了新见解,并确定胶质细胞Crq是这些过程的关键调控因子。

7神经重症与脑损伤 (2篇)

基础研究 (2篇)

Advanced healthcare materials IF 11.0 2026-10-06 PMID: 42839275
Mechanical forces shape brain development and contribute to pathological conditions such as traumatic brain injury. However, their direct effects on neural electrophysiology remain difficult to elucidate. Here, we introduce a multimodal system capable of delivering controlled mechanical actuation to brain spheroids while simultaneously recording their spontaneous electrophysiological activity. The platform enables culturing spheroids onto kirigami-patterned stretchable thin-film microelectrode arrays over multiple days. The array reliably records spontaneous spheroid activity and sustains uniaxial mechanical stimulation with controlled elongation and speed, ranging from manual precision stretching to high-velocity impacts. We capture spheroid deformation during slow stretch (∼100 µm/s) and detect acute electrophysiological changes following high-velocity stimulation (∼1-2 m/s). This multimodal platform establishes a foundational system for systematic in vitro investigations of how mechanical forces regulate functional activity in 3D tissues.
中文摘要:机械力塑造大脑发育,并促成创伤性脑损伤等病理状态。然而,机械力对神经电生理的直接效应仍难以阐明。在此,我们介绍一种多模态系统,能够向脑球体施加受控的机械驱动,同时记录其自发电生理活动。该平台可将球体在剪纸图案化可拉伸薄膜微电极阵列上培养多日。该阵列能可靠记录球体的自发活动,并承受单轴机械刺激,其伸长和速度可控,范围从手动精确拉伸到高速冲击。我们捕捉了慢速拉伸(约100 µm/s)期间的球体变形,并检测到高速刺激(约1–2 m/s)后的急性电生理变化。该多模态平台为系统性地在体外研究机械力如何调控三维组织中的功能活动建立了基础系统。
Acta biomaterialia IF 10.4 2026-10-02 PMID: 42826786
Neurological injuries remain difficult to treat due to the complex microenvironment and the limited intrinsic regenerative capacity of neural tissues. Recently, wireless neuromodulation based on piezoelectric nanomaterials, particularly barium titanate (BaTiO3), has emerged as a promising alternative to conventional implantable electrical stimulation. Polar BaTiO3 ceramics generally have higher piezoelectric charge coefficients than conventional Polyvinylidene Fluoride (PVDF) and Poly(vinylidene fluoride-co-trifluoroethylene) (P(VDF-TrFE)) films, are more resistant to degradation than ZnO, and are lead-free unlike Lead Zirconate Titanate (PZT), although their rigidity and potential persistence in tissue complicate soft-tissue integration and post-treatment clearance. This review systematically summarizes recent advances in BaTiO3-enabled piezoelectric neuromodulation and further outline preclinical applications in pain management and metabolic regulation across multiple neurological disorders, including traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), and post-traumatic epilepsy (PTE). We subsequently analyze the underlying mechanisms for neural repair, highlighting modulation of voltage-gated ion channels (e.g., Ca2+ and Na+) to regulate neuronal excitability and stem cell differentiation, mitochondrial targeting to influence metabolism and immune polarization, and controlled intracellular ion release (e.g., Zn2+) to modulate gene transcription. To enhance electromechanical-biological coupling in vivo, interface engineering strategies for BaTiO3 are also discussed, with emphasis on surface modification approaches such as polydopamine functionalization and integration with conductive hydrogels to improve biomechanical compatibility. Finally, key challenges for clinical translation, including the lack of standardized stimulation parameters, are addressed, providing insights for the development of next-generation neuromodulation-based therapies. STATEMENT OF SIGNIFICANCE: Neurological injuries and diseases represent some of the most formidable clinical challenges because neural tissues have limited regenerative capacity, whereas conventional wired electrical stimulation is invasive. Although BaTiO3-based piezoelectric nanomaterials have emerged as important wireless transducers for neuromodulation, the field still lacks a systematic framework linking the fundamental electromechanical properties of BaTiO3 to disease-relevant therapeutic mechanisms and barriers to clinical translation. This review provides a systematic, mechanism-oriented assessment of BaTiO3-based wireless neuromodulation by outlining its crystallographic basis and multiscale structural engineering and examining how localized electrical potentials may modulate voltage-gated ion channels, the neuroimmune microenvironment, and stem-cell metabolism. Ultimately, we critically analyze the prominent bottlenecks impeding preclinical-to-clinical translation, involving long-term biosafety, biomechanical compatibility, manufacturing reproducibility, etc.
中文摘要:神经损伤由于复杂的微环境和神经组织有限的内在再生能力,仍然难以治疗。近年来,基于压电纳米材料,尤其是钛酸钡(BaTiO3)的无线神经调控,已成为传统植入式电刺激的一种有前景的替代方案。极性BaTiO3陶瓷通常比传统聚偏氟乙烯(PVDF)和聚(偏氟乙烯-三氟乙烯)(P(VDF-TrFE))薄膜具有更高的压电电荷系数,比ZnO更耐降解,并且与锆钛酸铅(PZT)不同,不含铅,尽管其刚性及在组织中可能持续存在使软组织整合和治疗后清除变得复杂。本综述系统总结了BaTiO3赋能压电神经调控的最新进展,并进一步概述其在多种神经系统疾病中疼痛管理和代谢调控方面的临床前应用,包括创伤性脑损伤(TBI)、脊髓损伤(SCI)、周围神经损伤(PNI)和创伤后癫痫(PTE)。我们随后分析了神经修复的潜在机制,重点强调调节电压门控离子通道(如Ca2+和Na+)以调控神经元兴奋性和干细胞分化、靶向线粒体以影响代谢和免疫极化,以及控制细胞内离子释放(如Zn2+)以调节基因转录。为增强体内机电-生物耦合,还讨论了BaTiO3的界面工程策略,重点介绍表面修饰方法,如聚多巴胺功能化和与导电水凝胶整合,以改善生物力学相容性。最后,阐述了临床转化的关键挑战,包括缺乏标准化刺激参数,为开发下一代基于神经调控的疗法提供见解。意义声明:神经损伤和疾病代表一些最严峻的临床挑战,因为神经组织再生能力有限,而传统有线电刺激具有侵入性。尽管基于BaTiO3的压电纳米材料已成为神经调控的重要无线换能器,但该领域仍缺乏一个系统框架,将BaTiO3的基本机电特性与疾病相关治疗机制及临床转化障碍联系起来。本综述通过概述其晶体学基础和多尺度结构工程,并考察局部电势如何调控电压门控离子通道、神经免疫微环境和干细胞代谢,对基于BaTiO3的无线神经调控进行了系统、以机制为导向的评估。最终,我们批判性分析了阻碍临床前向临床转化的突出瓶颈,涉及长期生物安全性、生物力学相容性、制造可重复性等。